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Study of the putative roles of sirtuins 1 and 3 in the aristolochic acid I-induced 
cytotoxicity in human kidney-2 cells 
HARVENT Marianne 
Abstract  
Aristolochic acid nephropathy is characterized by a progressive interstitial fibrosis located in 
the superficial cortex, along with a tubular atrophy and a loss of proximal tubules due to the 
ingestion of aristolochic acids. In different study models of nephropathy, the effects of sirtuins 
1 and 3 have already been investigated as they have been shown to have protective roles 
against oxidative stress or mitochondrial impairment. However, the roles of these enzymes 
have never been investigated in a model of aristolochic acid nephropathy. In the first part of 
this study, an aristolochic acid I (AAI)-induced cytotoxicity in vitro model is used on human 
kidney-2 cells to determine these putative roles. To allow sirtuins 1 and 3 gene expression 
analysis in cells exposed to an AAI, independently of cell death, we have characterized the 
effects of low concentrations (0, 0.1, 0.25, 0.5, 0.75 or 1 µM) of AAI on cell proliferation and 
cell toxicity by MTT and LDH assays for 12, 24, 48 or 72 h. After setting up the cell model, 
the second part concerns the analysis of the ATP content of cells incubated with low 
concentrations of AAI by a bioluminescent method. Indeed, mitochondrial fragmentation 
observed in cells exposed to a toxic AAI concentration might be accompanied by ATP 
production alterations. These low concentrations don’t affect the ATP contents. The third part 
of this work covers the investigation of the putative effects of low concentrations of AAI on 
the abundance of sirtuins 1 and 3 at the transcriptomic and protein levels. No significant 
difference is observed on the expression of sirtuin 1 and sirtuin 3. The last part relates to the 
impact of the activation or the inhibition of sirtuins 1 and 3, by the use of four molecules. In 
order to evaluate a putative sensitisation by sirtuins inhibitors (3-TYP and EX527) or a 
potential protection by sirtuins activators (Coumarin and SRT2104) against the AAI-induced 
cytotoxicity, western blot analysis, MTT and LDH assays are performed. A slight activation 
of sirtuin 3 was noted with the use of 10 µM of Coumarin. No change is observed in the 
cytotoxicity by the use of 10 µM of 3-TYP, whereas a decrease of the cell proliferation is 
observed. As regards sirtuin 1, a reduction of the cell proliferation and an increase in the 
cytotoxicity are observed with the use of 25 µM of SRT2104. Moreover, a decrease of the cell 
proliferation is observed 72 hours after the incubation with 10 µM of EX527. This study 
opens the scope for additional experiments such as the analysis of the morphology of the 
mitochondrial population in human kidney-2 cells exposed to low concentrations of 
aristolochic acid I or an increase of the concentrations of activators or inhibitors of sirtuins 
used in this work, in order to obtain a more marked effect of these four molecules. 
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Étude des rôles potentiels des sirtuines 1 et 3 dans la cytotoxicité induite par 
l’acide aristolochique I dans les cellules rénales humaines 
HARVENT Marianne 
Résumé 
La néphropathie aux acides aristolochiques est caractérisée par une fibrose interstitielle 
progressive au niveau du cortex superficiel ainsi que d’une atrophie tubulaire et d’une perte 
des tubules proximaux suite à l’ingestion d’acides aristolochiques. Les effets des sirtuines 1 et 
3 ont déjà été investigués dans différents modèles d’étude de néphropathie, montrant des rôles 
protecteurs contre le stress oxydatif ou les altérations mitochondriales. Cependant, les rôles 
potentiels de ces deux enzymes n’ont jamais été étudiés dans la néphropathie aux acides 
aristolochiques. Dans la première partie de ce travail, un modèle in vitro de cytotoxicité 
induite par l’acide aristolochique I (AAI) est utilisé sur des cellules rénales humaines pour 
déterminer ces rôles potentiels. Afin d’analyser l’expression génique des sirtuines 1 et 3 dans 
des cellules exposées à l’AAI, indépendamment de la mort cellulaire, les effets de faibles 
concentrations (0, 0,1, 0,25, 0,5, 0,75 ou 1 µM) d’AAI sur la prolifération et la toxicité 
cellulaires ont été déterminés par des tests MTT et LDH durant 12, 24, 48 ou 72 heures. Après 
cette mise au point, la seconde partie concerne l’analyse des niveaux d’ATP des cellules 
incubées avec les faibles concentrations d’AAI choisies, niveaux évalués par une méthode de 
bioluminescence. En effet, la fragmentation mitochondriale observée dans des cellules 
exposées à une concentration toxique d’AAI pourrait être accompagnée d’altérations de la 
production d’ATP. Ces faibles concentrations n’affectent pas le contenu en ATP. La troisième 
section de ce travail couvre l’examen des effets potentiels de faibles concentrations d’AAI sur 
l’abondance des sirtuines 1 et 3 au niveau transcriptomique et protéique. Aucune différence 
significative n’a été observée au niveau de l’expression de sirtuine 1 et de sirtuine 3. La 
dernière partie de ce travail est relative à l’activation ou l’inhibition des sirtuines 1 et 3 par 
l’usage de quatre molécules. Afin d'évaluer la sensibilisation potentielle par les inhibiteurs (3-
TYP ou EX527) ou une potentielle protection par les activateurs (Coumarin ou SRT2104) de 
sirtuines contre la cytotoxicité induite par l’AAI, les méthodes de western blot, MTT et LDH 
furent appliquées. Une faible activation de la sirtuine 3 a été constatée lors de l’utilisation de 
10 µM de Coumarin. Aucun changement n’a été observé dans la cytotoxicité en utilisant 10 
µM de 3-TYP, tandis qu’une diminution de la prolifération cellulaire a été relevée. En ce qui 
concerne la sirtuine 1, une diminution de la prolifération cellulaire et une augmentation de la 
cytotoxicité ont été constatées en utilisant 25 µM de SRT2104. De plus, une réduction de la 
prolifération cellulaire a été observée 72 heures après incubation avec 10 µM d’EX527. Cette 
étude ouvre le champ à des expériences additionnelles telles que l’analyse de la morphologie 
de la population mitochondriale dans des cellules rénales humaines soumises à de faibles 
concentrations d’AAI ou une augmentation de la concentration des activateurs ou inhibiteurs 
de sirtuines utilisés dans ce travail afin d’obtenir un effet plus marqué des quatre molécules. 
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Introduction 
 
I. The kidneys 
a) Anatomy  
The kidneys are located in the abdominal cavity, under the diaphragm, in the 
retroperitoneum. They are vascularized by the renal arteries, which give birth to segmental 
arteries and then to interlobate, arcuate and interlobular arteries that supply afferent arterioles 
and the glomerulus where the filtration occurs. Blood then goes to the efferent artery, which 
gives birth to vasa recta that give birth to venous system (Figure 1) (Gueutin et al., 2012). 
 
Figure 1: Renal anatomy and vascularization. Modified from (Gueutin et al., 2012). 
From the outside to the inside, the composition of the kidney is the following: 1) cortex, 
2) outer stripe of the outer medulla (OSOM), 3) inner stripe of the outer medulla (ISOM) and 
4) inner medulla (Figure 2). The primitive urine flows through the proximal convoluted tubule 
(PCT), the Henle’s loop (HL), then the distal convoluted tubule (DCT), and finally, through 
the collecting duct (CD) where the reabsorption and secretion mechanisms allow to modulate 
the urinary concentration (Gueutin et al., 2012). 
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Figure 2 : Illustration of a nephron, the functional unit of kidneys, forming by glomerulus and renal tubules. 
1, glomerulus; 2, proximal convoluted tubule; 3, proximal straight tubule; 4, descending thin limb; 5, ascending 
thin limb; 6, thick ascending limb; 7, macula densa; 8, distal convoluted tubule; 9, connecting tubule; 10, 
cortical collecting duct; 11, outer medullary collecting duct; 12, inner medullary collecting duct (Mount, 2014). 
b) Functions 
The kidneys ensure several functions: elimination of degradation products of the cellular 
metabolism such as urea, maintenance of the composition of the inner medium (water and 
electrolyte homeostasis) and synthesis of renin
2
, erythropoietin
3
 and calcitriol
4
 (Lacour, 
2013). They are also in charge of the regulation of intra-/extracellular volume, acid-base 
status, pH regulation, erythropoiesis and calcium and phosphate concentration homeostasis 
(Gueutin et al., 2012). 
These organs filter every day about 150 to 180 L of blood to produce 1 to 2 L of urine, 
which is composed of metabolic waste products such as nitrogenous waste and extra fluids. 
Kidneys constitute a frequent target of toxicity induced by drugs, xenobiotics (Bajaj et al., 
2018) and cytotoxins (Hagos and Wolff, 2010). Indeed, the renal proximal tubules, part of the 
nephron in charge for secretion and reabsorption, have number of secretory transporters. So, 
kidneys possess a lot of passages and are most affected by the intoxication of toxic molecules. 
In addition, if transporters have an activity default, which can decrease their secretion activity, 
the toxic can potentially accumulate in the concerned cells (Hagos and Wolff, 2010). 
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 Molecule synthetized by juxtaglomerular cells after a decrease of the blood pressure. That allows the 
transformation of angiotensinogen to angiotensin I (Lacour, 2013) 
3
 Molecule produced by the kidney and essential for the production of erythrocytes (Lacour, 2013) 
4
 Or active vitamin D, increases the calcium and phosphate absorption by the organism and regulates also the 
parathormone in order to regulate the osteoblast activity (Lacour, 2013) 
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The nephron constitutes the functional unit of the kidney since it is able to achieve all the 
kidney functions, and it is composed of a glomerulus and of renal tubules (Callard, 2016). The 
PCT allows the most important reabsorption of water, sodium, bicarbonate, amino acids and 
small filtered proteins (Gueutin et al., 2012). The tubular reabsorption is the passage of a 
solute from urine to blood (Lacour, 2013) and so the proximal tubule allows a quantitative 
and qualitative modifications of urine (Callard, 2016). Indeed, the PCT possesses cubic 
epithelial cells with a lot of mitochondria, which offer the energy supply necessary for their 
function (Lacour, 2013). A major feature of proximal tubular cells (PTC) is the brush border 
in the lumen which contains microvilli (Callard, 2016). The different functions of PCT 
(Figure 3), mentioned above, are: 1) a total absorption for glucose, amino acids and low 
molecular weight proteins
5
; 2) an almost total reabsorption of bicarbonates and phosphates;  
3) the reabsorption of other ions such as Na
+
, K
+
, Cl
-
, Ca
2+
 and water that represent 75 % of 
filtered quantities, except for the Mg
2+
, and 4) the secretion of H
+
 ions and NH3 (Lacour, 
2013). 
 
Figure 3: Schematic illustration of PCT’s functions, based on (Zhuo and Li, 2013). 
 
II. Aristolochic acid nephropathy 
a) History and clinical features 
Aristolochic acid nephropathy (AAN) was initially described in the early 1990s in 
Belgium, when several young women were hospitalized with an interstitial nephritis from 
unknown origin. Rapidly, their nephritis appeared to be due to the use of slimming pills 
containing Chinese herbs (Vanherweghem et al., 1993). These patients received pills in which 
the harmless herb Stephania tetrandra was accidentally substituted by Aristolochia fangchi, 
which contains aristolochic acids (AA). Renal biopsies of these patients revealed that their 
kidneys were shrunk and asymmetric (Figure 4 A). In addition, the cortex was thinner than the 
cortex of a healthy kidney (Nortier et al., 2015). Histologically, the glomeruli seemed 
unaffected while an extensive and progressive interstitial fibrosis, mainly located in the 
cortex, was observed along with atrophy of proximal tubules (Figure 4 B). Additionally, 
interstitial infiltration by inflammatory cells was reported (Debelle et al., 2008; Jadot et al., 
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 Such as parathormone, growth factors or β2-microglobulin (Yu et al., 1983) 
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2017b). Indeed, it was described that proximal tubular epithelial cells (PTEC) constitute the 
preferential target of AA in kidneys (Debelle et al., 2008). 
 
Figure 4: Comparison between a healthy kidney and a kidney intoxicated by AA (A) (Nortier et al., 2015). 
Histological representation of kidney from patients with AAN which shows interstitial fibrosis and tubular 
atrophy (B) (Debelle et al., 2008). 
In addition, other features that support alterations of the kidney function are observed in 
patients intoxicated with AA. These alterations can be an increase in serum creatinine, a 
decrease in urinary excretion of neutral endopeptidase (NEP) which is found in brush border 
of proximal tubule and a proteinuria of low molecular weight proteins. These proteins are β2- 
and α1-microglobulin, cystatin C, Clara cell protein and retinol binding protein (RBP) (Jadot 
et al., 2017b; Nortier et al., 2015). Finally, these patients also frequently developed urothelial 
malignancies (Debelle et al., 2008; Vanherweghem et al., 1993). The abundance of several 
low molecular weight protein markers (filtered by glomerulus and then completely reabsorbed 
by proximal tubule where there are degraded) can be followed to assess kidney function 
alterations (Yu et al., 1983). 
The accumulation of α1-microglobulin in urine is an indirect reflect of tubular 
impairment. This protein (30 kDa), mainly synthetized in liver and kidney, is a lipocalin and 
can bind small hydrophobic ligand, such as steroids and retinoids. Compared to other protein 
markers of tubulopathies, the α1-microglobulin possesses the advantages to be stable in urine, 
even acid, and thus represents a sensitive marker of tubulopathies (Penders and Delanghe, 
2004; Yu et al., 1983). This protein exerts several functions such as the inhibition of 
lymphocyte activation in response to protein antigens, the stimulation of lymphocyte division 
or the inhibition of neutrophil granulocyte migration in vitro (Penders and Delanghe, 2004). A 
second protein used as a kidney function alteration, the β2-microglobulin (11.8 kDa), is the 
light chain common to the HLA-A, -B, and -C major histocompatibility complex antigens, 
and thus, is expressed on the surface of all normal nucleated cells (Bethea and Forman, 1990) 
and found in most biological fluids, including serum, urine and synovial fluid (Li et al., 2016). 
A serum elevation of this protein appears in kidney’s diseases but also in lymphoid 
malignancies, some chronic inflammatory or possibly autoimmune conditions (Bethea and 
Forman, 1990). In kidneys, the dysfunction of glomeruli would cause an increase in blood and 
a decrease in urine while, in contrast, the dysfunction of tubules would cause an increase in 
urine and a decrease in blood (Li et al., 2016). A third protein used as a marker is the    
retinol-binding protein 4 (RBP4) (21 kDa), a lipocalin synthetized by the liver and adipocytes, 
which can bind molecules such as steroids, bilins, retinoids and some lipids. It transports the 
vitamin A in the circulation in retinol form, from liver to target tissues (skin, mucosa and 
retina). It can also serve as a marker to malnutrition, type II diabetes or tubular nephropathy 
(Biomnis, 2012). The fourth protein used as a marker, the cystatin C (13.2 kDa), is 
synthetized in a stable rate, not influenced by renal factors (Murty et al., 2013), produced by 
all investigated nucleated cells (Coll et al., 2000) and widely distributed in human body fluids. 
It inhibits the activity of lysosomal cysteine proteinases and plays a key role in various 
diseases. The cystatin C exerts several functions, among which: 1) direct inhibition of 
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endogenous or exogenous cysteine peptidases; 2) a modulation of the immune system and    
3) antibacterial and antiviral activities (Mussap and Plebani, 2004). The last protein, Clara cell 
protein (15.8 kDa), is produced and secreted by only a few cell types (epithelial cells …). It 
has the anti-inflammatory property by the inhibition of the phospholipase A2 (PLA2) (Jorens 
et al., 1995; Kabanda et al., 1995). 
The presence of these five low molecular weight proteins attests that tubules are injured 
after AA intoxication. Moreover, 1) low molecular weight proteins/albumin ratio - higher in 
patients with tubular diseases than in patients with glomerular diseases -, 2) decrease in the 
urinary level of NEP
6
, 3) decrease in the megalin
7
 expression, which is in conjunction with 
the inhibition of receptors-mediated endocytosis of low molecular weight proteins, and         
4) transport of AA by organic anion transporter (OAT) - expressed in membranes of PTEC -, 
indicate PTEC as the main target of AA (Debelle et al., 2008). Indeed, PTEC reabsorb 
proteins mainly by receptor-mediated endocytosis. That implies 1) the binding to a receptor in 
the luminal membrane of epithelial cells, 2) the endocytosis of the protein-receptor complex, 
3) the catabolism of the protein in lysosomes and 4) the receptor recycling to the luminal 
membrane (Lebeau et al., 2001). This process of reabsorption involves megalin and cubilin
8
 
receptors, located both in the brush border of PTEC (Li et al., 2018; Sansoe et al., 2006; 
Verroust et al., 2000). An exposure of 20 µmol/L of AA on opossum kidney (OK) cells for  
24 h decreases the megalin expression (Lebeau et al., 2001). In addition to the proteins 
mentioned above, several proteins present in brush border have a modified level after an 
exposure to AA. These proteins are leucine aminopeptidase, N-acetyl-β-D-glucosaminidase 
and α-glutathione S-transferase. Moreover, PTEC show morphological changes, including the 
loss of brush border (Lebeau et al., 2005). 
b) Balkan-endemic nephropathy or BEN 
As already mentioned, AAN has been described in Belgium only in the early 1990s 
(Vanherweghem et al., 1993). In fact, the true incidence of AAN was and remains largely 
unknown and probably underestimated due to the use of AA in traditional medicine in Asia 
and the availability of AA-containing products on Internet. In addition, AA have also been 
found to be the toxicological agent responsible for the Balkan-endemic nephropathy (BEN). 
Many people are intoxicating mainly in rural areas of the Balkan countries (Bosnia, Bulgaria, 
Croatia, Romania and Serbia) by eating contaminated food. In fact, these individuals have a 
chronic dietary intoxication from bread which is made from wheat flour contaminated with 
Aristolochia. This plant grows in wheat fields of endemic areas and is mixed with wheat grain 
(Figure 5). BEN, recognized since late 1950s, is characterized by a tubulointerstitial fibrosis, 
slow progression to end-stage renal disease (for 20 years or more) and urothelial malignancy. 
In these countries, 25000 people are suffering from BEN and more than 100000 people are at 
risk. So the impact of AA exposure has a worldwide impact (Debelle et al., 2008; Nortier et 
al., 2015). However, BEN and AAN, although sharing similar features, present differences 
mainly in the clinical course. Indeed, AA are ingested in small doses in BEN whereas in AAN 
induced by slimming pills, AA are ingested in higher doses (0.65 ± 0.56 mg/g of powder in 
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 Membrane-bound Zn-metallo-endopeptidase of the brush border membrane of PTEC, which degrades several 
peptides (atrial natriuretic peptide or endothelin-1) and produces the vasoconstrictor polypeptide endothelin-1 
from circulating precursors (Sansoe et al., 2006) 
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 Megalin, or low-density lipoprotein-related protein-2 (LRP2), is a 600-kDa protein that belongs to the         
low-density lipoprotein receptor (LDLR) family. It is membrane-anchored ligand highly expressed on the apical 
surface of PTEC, where it plays an important role in the reabsorption of filtered vitamins and proteins from the 
glomeruli; it binds and internalizes proteins with a molecular weight lower than albumin, and is implicated in 
vitamin D uptake (Li et al., 2018) 
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 Cubilin, or receptor for the intrinsic factor-vitamin B12 complex, is a 460-kDa protein that helps the megalin in 
the reabsorption of proteins and vitamins into PTEC (Verroust et al., 2000) 
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pills) (Jadot et al., 2017b; Vanherweghem and al., 2003). Still, BEN can be considered as an 
environmental form of AAN (Jadot et al., 2017b).  
 
Figure 5: Plants of Aristolochia growing in fields in Serbia (A) and Croatia (B) (Nortier et al., 2015). 
 
III. Aristolochic acid  
a) Aristolochic acid structure and activity 
AA, that plays a major role in kidney toxicity, is composed of a mixture containing AAI 
(8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid) and AAII (6-nitro-
phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid) which are nitrophenanthrene carboxylic 
acids (Figure 6) found in the roots and leaves of Aristolochia species. Both compounds have 
similar genotoxic and carcinogenic potential and are both cytotoxic, but only AAI is 
nephrotoxic (Romanov et al., 2015; Shibutani et al., 2007). Indeed, according to Shibutani and 
his colleagues, AAI-treatment in C3H/He mice is associated with strong nephrotoxic effects 
characterized by acute tubular necrosis, extensive cortical interstitial fibrosis, mild interstitial 
inflammation and occasional tubular apoptosis, compared to control mice. In addition, 
treatment with AAII only induced a slight acute necrosis without renal interstitial fibrosis 
(Shibutani et al., 2007). Moreover, levels of AAI-DNA adducts (metabolite that will be 
explained in the following section) observed in kidneys are more abundant than in other 
organs such as stomach, spleen or lung. Furthermore, levels of AAII-DNA adducts in        
non-target tissues (liver, intestine, stomach and lung) are less abundant than those in mice 
treated with AAI. These results suggested that kidneys are the primary target of AA and that 
AAI is the chemical species responsible for the nephrotoxic effects of AA. It is due to the 
presence of an O-methoxy group at position C-8 in the nitrophenanthrene ring, only in AAI. 
Indeed, its derived-metabolite such as AAIa, generated by demethylation of the O-methoxy 
group, is not toxic for renal epithelial cells in culture (Shibutani et al., 2007).  
 
Figure 6: Molecular structure of aristolochic acids I and II. Formula of the major compounds of the 
Aristolochia species, aristolochic acid I (AAI) and aristolochic acid II (AAII) (Jadot et al., 2017b). 
b) Aristolochic acid transport and metabolization 
After oral ingestion, AA are absorbed from the gastrointestinal tract and distributed 
throughout the body in a systemic manner. In addition, once in blood circulation, AAI is able 
to bind to plasma proteins such as albumin (Jadot et al., 2017b). As a consequence of this 
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binding, AAI cannot be filtered in the glomerulus and goes through the peritubular capillaries. 
AAI is then transported by organic anion transporters (OAT) 1, OAT2 and OAT3 at the 
basolateral membrane of PTEC (Jadot et al., 2017b). In fact, the hydrophobic moiety of 
substrate of OAT1 must be of 4-10 Å and that of AAI is about 7-8 Å (Xue et al., 2011). In 
addition, AAI competitively inhibits anion transport mediated by OAT1, OAT3 and OAT4, in 
a dose-dependent manner, and with a stronger effect on OAT1 and OAT3 (Babu et al., 2010; 
Bakhiya et al., 2009). AAI metabolites are then secreted in the proximal tubular lumen by 
OAT4 or, hypothetically, by multidrug resistance-associated proteins (MRP) 2 and 4 at the 
apical membrane. The major metabolites, called the aristolactams, are sequestered inside the 
cell due to the formation of DNA adducts (Figure 7) (Jadot et al., 2017b). So, OATs 
contribute to the accumulation of AAI and AAI metabolites in the cells (Bakhiya et al., 2009). 
However, the role of OATs in an AA nephropathy requests more investigations (Jadot et al., 
2017b). It is possible to block the entry of AA in PTEC by triggering the inhibition of OATs 
by using of probenecid, an OAT inhibitor (Bakhiya et al., 2009; Baudoux et al., 2012). This 
compound is considered as a renal protective effect as it reduces the histopathologic injuries 
in mice exposed to AA (Xue et al., 2011). The OATs inhibition leads to a reduction of AA-
DNA adduct and a preservation of cell viability, in addition to a reduction in the abundance of 
proliferating cell nuclear antigen (PCNA), a marker of DNA-damage-repair. However, in 
response to the inhibition of OAT, it appears that AAI can enter by other endogenous 
transmembrane transporters or by passive diffusion (Baudoux et al., 2012).  
 
 
Figure 7: AAI transport in PTEC. After binding to albumin, AAI is transported through the basolateral 
membrane via OAT1, OAT2 and OAT3 and then metabolized in aristolactams. The formation of DNA adducts is 
induced by the binding of AA metabolites to DNA. The metabolites are secreted through the apical membrane 
via OAT4 and hypothetically via MRP2 and 4 (Jadot et al., 2017b). 
After reduction, AAI is metabolized in N-hydroxyaristolactam I and it is further reduced 
to cyclic N-acylnitrenium ions, to 7-hydroxyaristolactam I or to aristolactam I, the major 
metabolite of AAI. The nitrenium ion displays a delocalized positive charge able to bind to 
the exocyclic amino groups of purine bases and, ultimately, to form  
AA-DNA adducts (Stiborova et al., 2017). DNA adducts induce DNA damage with severe 
nuclear alterations, cell cycle arrest and apoptosis and may lead to urothelial malignancies, 
carcinoma and upper urinary tract cancers (Li et al., 2006; Shibutani et al., 2007). They are 
detected by high-performance liquid chromatography coupled with mass spectrometry (Yuan 
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et al., 2009), by 
32
P-postlabelling technique or with rabbit monoclonal anti-AL adduct 
antibodies (Chang et al., 2017; Shibutani et al., 2007). They can thus be used as biomarkers 
after exposure to AA (Jadot et al., 2017b; Nortier et al., 2015; Schmeiser et al., 1996; 
Stiborova et al., 2017).  
Several enzymes are critical in AA metabolism (Figure 8). The major enzymes for the 
oxidation of AAI are the human cytochrome P450 (CYP) enzymes CYP1A1 and 1A2. Other 
enzymes (CYP2C, CYP3A…) can act but with less efficiency due to their lower affinity for 
AAI. Some enzymes are implicated in the reduction of AAI. The major reductase is the 
cytosolic NAD(P)H:quinone oxidoreductase (NQO1). In addition, it has been shown in 
human kidney (HK)-2 cells that sulfotransferase SULT1A1 potentiates the activation of AAI 
and N-hydroxyaristolactam I even if, in others studies, SULT has no action on the 
bioactivation of AAI or AAII. A third enzyme, the NADPH:CYP oxidoreductase (POR) 
interacts in the reduction of AAI on a minor manner. CYPs have two actions: they reduce 
AAI and AAII and, in addition, they oxidize AAI. The fact that CYP1A1 and CYP1A2 act as 
oxidant and reductive enzymes is important, because a balance between detoxification and 
activation reactions of AAI is a critical determinant in the development of AAN or BEN. 
Additionally, several endogenous factors might also contribute to disease development such 
as the expression levels and activities of biotransformation enzymes dependent on their basal 
expression, regulation, induction and/or inhibition. Other factors are the genetic and 
phenotypic polymorphisms of these enzymes (Stiborova et al., 2017). 
 
Figure 8: Metabolism of AAI. There are two pathways for AAI metabolism: the activation or the detoxification. 
Formation of N-hydroxyaristolactam I is mediated by reduction of AAI and this metabolite is either further 
reduced to aristolactam I (the major metabolite of AAI) or rearranged to 7-hydroxyaristolactam I. In addition, 
AAIa is formed through O-demethylation of AAI. CYP: hepatic microsomal cytochrome P450, NQO1: hepatic 
and renal cytosolic NAD(P)H:quinone oxidoreductase, POR: kidney microsomal NADPH:CYP oxidoreductase 
(Stiborova et al., 2017). 
c) Aristolochic acid effects 
AA can induce inflammation by the decrease in the protein phosphatase magnesium-
dependent 1A (PPM1A) expression, which leads to the enhanced phosphorylation of IKKβ 
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and activation of inflammatory genes driven by nuclear factor-kappa B (NF-κB) transcription 
factor (Sun et al., 2009). PPM1A, an IKKβ phosphatase (subunit of activated IκB kinase), can 
dephosphorylate IKKβ at Ser177 and Ser181 (essential for activation of IKKβ by tumour-
necrosis factor alpha - TNF-α) and terminate IKKβ-mediated NF-κB activation. After 
phosphorylation and activation of IKKβ by TNF-α, IKKβ binds to PPM1A, but when the 
expression of PPM1A is reduced, this binding does not happen (Sun et al., 2009). However, 
AA are also known as anti-inflammatory compounds in traditional medicine in Asia (Chen et 
al., 2010). On the one hand, AAI inhibits PLA2 activity in human neutrophils. But on the 
other hand, a daily treatment of male Wistar rats with AA leads to massive interstitial 
inflammation. The use of AAI induces a decrease in the DNA-binding activity of NF-κB by 
an inhibition of the phosphorylation of IκBα, an inhibitor of NF-κB. Overall suggests that 
AAI prevents NF-κB activation by blocking IκBα phosphorylation (Liu et al., 2011). 
It was also reported that AAI causes mitochondrial alterations. Mitochondria are involved 
in several essential cellular functions such as cell cycle, growth, differentiation and death. The 
organelle, providing ~90 % of cellular ATP by oxidative phosphorylation (OxPHOS), is a 
significant source of reactive oxygen species (ROS), which, produced in excess, can lead to 
mitochondrial dysfunction, disruption and cell death. Mitochondria are composed of: 1) the 
outer membrane, permeable barrier to metabolites and small peptides (< 5000 Da) and with a 
similar composition to the plasma membrane, 2) the inner membrane, electrical insulator 
(Benigni et al., 2016), 3) an intermembrane space, which separate the both membranes and 
whom the composition is similar to the cytosol and 4) the matrix, the site of the tricarboxylic 
acid/Krebs cycle (Cooper, 2000). The structure and function of mitochondria are perpetually 
remodelled in response to metabolic changes and are controlled by fusion, fission, motility 
and morphological process. These changes refer to mitochondrial dynamics and help to 
maintain mitochondrial functional integrity. Fusion is mediated by mitofusin (Mfn) 1 and 2 
for the outer membrane and optic atrophy protein 1 (OPA-1) for the inner membrane. While 
fission is mediated by cytosolic dynamin-related protein (Drp) 1 and its outer membrane 
receptors (mitochondrial fission factor (Mff), fission 1 (Fis1) and the 49 and 51 kDa 
mitochondrial dynamics proteins (MiD49-51)) (Figure 9) (Benigni et al., 2016). 
 
Figure 9: Mitochondrial dynamics. Mitochondrial fission (A) and mitochondrial fusion (B). Drp1, dynamin-
related protein 1; Fis1, fission 1; Mff, mitochondrial fission factor; MiD49 and MiD51, mitochondrial dynamics 
proteins of 49 and 51 kDa; Mfn1/2, mitofusin 1 and 2; OPA1, optic atrophy protein 1. 
As PTEC possess number of mitochondria, these cells are much vulnerable to 
mitochondrial dysfunction. The impairments that AAI can induce: 1) mitochondrial swelling, 
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2) leakage of Ca
2+
, 3) membrane depolarisation and 4) release of cytochrome c from kidney 
mitochondria. In addition, rats intoxicated with 5 mg/kg/day have proximal tubular enlarged, 
dysmorphic mitochondria, mitochondrial swelling and small vacuoles. The degradation and 
the decrease in the number of mitochondria are proportional to the AAI concentration used 
(Jiang et al., 2013). The ATP content also decreases in response to AA exposure in a 
concentration-dependent manner and a depletion of mitochondrial DNA (mtDNA) can also be 
observed (Jiang et al., 2013). Nuclear DNA (nDNA) is less susceptible to damage induced by 
AAI than mtDNA, due to the absence of efficient DNA repair mechanisms in mitochondria 
and the lack of protective histones in mtDNA (Jiang et al., 2013; Tabara et al., 2014). 
Moreover, with an exposure of 5 µM of AAI for 24 h, a decrease in the cellular content of 
ATP is observed in HK-2 cells (Qi et al., 2007). Finally, to accompanied these mitochondrial 
modifications, the production of ROS is increased (Shui et al., 2017). 
AA also play a role in fibrosis. Indeed, in the HK-2 cells exposed to AA, the expression 
of phosphatase and tensin homolog (PTEN), which interacts with PPM1A
9
 by stabilizing its 
expression, is reduced. This reduction of PTEN expression induces three reactions: 1) a 
reduction of total PPM1A expression, 2) a decrease in nuclear PPM1A levels and 3) an 
increase in PPM1A in the cytosolic fraction. Finally, the TGF-β1/Smad3 signalling is 
activated after an increase in Smad2/3 phosphorylation (Figure 10). There is then the 
association of Smad2/3 with Smad4 and an increase in Smad2 accumulation in the nucleus as 
well as the enhancement of the production of fibrotic factors (Figure 10) (Lin et al., 2006; 
Samarakoon et al., 2016). 
 
Figure 10: Schematic representation of role of PPM1A on the TGF-β1 signalling. Phosphorylation of 
Smad2/3 is essential for the association with Smad4 and the nuclear import. PPM1A binds to phosphorylated 
Smad2/3, promoting the dissociation of the Smad2/3-Smad4 complex and so facilities nuclear export of Smad2/3. 
TβRI, type I TGF-β receptor; TβRII, type II TGF-β receptor; TFX, hypothetical DNA-binding cofactor for 
Smads; GTF, general transcription machinery (Lin et al., 2006). 
As regards oxidative stress, it has been shown that AAI-intoxication induces glutathione 
(GSH) depletion in rats. A hypothesis is that rat organic anion transporter (OAT) serves as a 
bidirectional transporter for the organic anion/GSH exchange (Yu et al., 2011). 
                                                          
9
 Monomer located in cytosol, cytoplasmic vesicle, nucleus and membrane, which binds 2 magnesium or 
manganese ions per subunit. This protein is member of the PP2C family of serine/threonine protein 
phosphatases, which is known to be negative regulators of cell stress response pathways (websites of antibodies-
online and uniprot) 
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At the present time, sirtuins expression and activity in response to AA exposure as well 
as the mechanism triggered by these proteins to reduce cytotoxicity and nephrotoxicity remain 
poorly investigated. 
 
IV. Sirtuins  
a) Structure, function and catalysed activities 
Sirtuins are a well-conserved evolutionary family of nicotinamide adenine dinucleotide 
(NAD+)-dependent enzymes with deacetylase, mono-ADP-ribosyltransferase, demalonylase 
or desuccinylase activity (Houtkooper et al., 2012; Nogueiras et al., 2012; Polak-Jonkisz et 
al., 2013). Sirtuins target histones and non-histone proteins, among which transcription factors 
(nuclear factor-kappa B - NF-κB, or peroxisome proliferator-activated receptor-γ - PPARϒ), 
metabolic enzymes (glutamate dehydrogenase - GDH, or acetyl-CoA-synthase - AceCSs) and 
antioxidant enzymes (isocitrate dehydrogenase 2 - IDH2, or superoxide dismutase 2 - SOD2) 
(Nogueiras et al., 2012; Yu and Auwerx, 2009).  As sirtuins activities are dependent of NAD
+
 
concentrations, they are called “cellular energy sensors” which directly link them to 
metabolism (Nogueiras et al., 2012). As represented in Figure 11, sirtuins deacetylate proteins 
or enzymes in the presence of NAD
+
 used as a co-substrate. First, sirtuins catalyse the 
cleavage of NAD
+
, producing nicotinamide (NAM) and 2’-O-acetyl-ADP-ribose. NAM is 
then regenerated into NAD
+
 thanks to several enzymes (Kupis et al., 2016). 
 
Figure 11: Deacetylation mechanism of sirtuins (Kupis et al., 2016). 
Mammals possess seven sirtuins (SIRT1-7) sharing a conserved catalytic domain, flanked 
by the N- and C-terminal sequences of variable length (Carafa et al., 2012). These sequences 
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are the targets for post-translational modifications affecting the functions and/or the activity 
of sirtuins (Figure 12) (Carafa et al., 2012; Yamamoto et al., 2007).  
 
Figure 12: Post-translational modifications of SIRT1 and SIRT3. Blue boxes, catalytic core domain; grey 
boxes, N- and C-terminal sequences; ESA, essential for SIRT1 activity. Modified from (Flick and Luscher, 2012). 
However, these proteins are localized in different subcellular compartments and have 
different functions (Carafa et al., 2012; Yamamoto et al., 2007). The eukaryotic sirtuins were 
divided into four phylogenetic categories: SIRT1, SIRT2 and SIRT3 composing the class I 
(deacetylase), SIRT4 constituting the class II (ADP-ribosyltransferase), SIRT5 for the class 
III (deacetylase, demalonylase or desuccinylase) and, finally, SIRT6 and SIRT7 as the class 
IV (deacetylase/ADP-ribosyltransferase and deacetylase, respectively). SIRT 1, 6 and 7 are 
nuclear, SIRT2 is cytosolic and SIRT 3, 4 and 5 are mainly localized into mitochondria 
(Carafa et al., 2012; Houtkooper et al., 2012). 
Protein Class Localization Function(s) 
SIRT1 I Nucleus Deacetylase 
SIRT2 I Cytosol Deacetylase 
SIRT3 I Mitochondria  Deacetylase 
SIRT4 II Mitochondria ADP-ribosyltransferase 
SIRT5 III Mitochondria Deacetylase/ 
demalonylase/ 
desuccinylase 
SIRT6 IV Nucleus Deacetylase/ 
ADP-ribosyltransferase 
SIRT7 IV Nucleus Deacetylase 
Figure 13: Summary of classes of sirtuins (Carafa et al., 2012; Houtkooper et al., 2012). 
b) Sirtuins 1 and 3 regulation 
The regulation of SIRT1 expression and activity is complex. Firstly, the gene promoter is 
positively and negatively regulated by the binding of various transcription factors.  
Hypermethylated in cancer 1 (H1C1) is a transcriptional repressor and the repression is 
mediated by carboxy-terminal-binding protein (CtBP) which is also a transcriptional 
repressor. E2 promoter binding factor 1 (E2F1) is a positive regulator of SIRT1 and p53 is a 
negative regulator. Finally, FOXO3a inhibits the suppressive action of p53 (Figure 14) 
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(Zschoernig and Mahlknecht, 2008). The acetylation and activity of these factors are in turn 
controlled by SIRT1. Secondly, the SIRT1 mRNA is regulated by the RNA binding protein 
HuR and miR-34A, a p53-regulated microRNA. Thirdly, SIRT1 protein activity is regulated 
positively and negatively by interacting proteins (active regulator of SIRT1 - AROS, and 
deleted in breast cancer 1 - DBC1) and by NAD
+
/NADH ratio (Figure 14) (Finkel et al., 2009; 
Houtkooper et al., 2012). 
 
Figure 14: Regulation of SIRT1 activity (Finkel et al., 2009). 
The expression of SIRT3 is activated by estrogen-related receptor-α (ERRα). In addition 
to ERRα that binds to SIRT3 promoter, peroxisome proliferator-activated receptor γ 
coactivator-1 alpha (PGC-1α) binds the transcription factor (co-activator) and controls the 
expression of genes involved in the biogenesis of mitochondria, brown adipose tissue 
development and function (Houtkooper et al., 2012). A major function of PGC-1α is the 
detoxification of ROS which are generated during the mitochondrial respiration. PGC-1α 
controls the removal of ROS by the regulation of the expression of several enzymes of 
detoxification such as SOD2. In addition, PGC-1α increases the expression of the 
transcription factors nuclear respiratory factors (NRF), which regulate the expression of 
several mitochondrial genes. For example, PGC-1α actives NRF1 in order to regulate the 
expression of transcription factor A mitochondrial (TFAM), which is responsible for the 
transcription and replication of mitochondrial genes from the mitochondrial genome (Austin 
and St-Pierre, 2012). 
c) Sirtuins 1 and 3 functions 
SIRT1 deacetylates target proteins involved in several cellular processes such as cell 
cycle, mitochondrial biogenesis, metabolism, inflammation, fibrosis and adaptation to cellular 
stress (Kitada et al., 2013; Nogueiras et al., 2012).  
The activation of SIRT1 prevents renal fibrosis, that may be caused by AA, in response to 
the deacetylation of Smad3 (that inhibits the activity of the transforming growth factor beta 1 
(TGF-β1)) inhibiting the cell signalling triggered by this transcription factor. The TGF-β1 is a 
cytokine known to positively control the expression of genes encoding collagen IV and 
fibronectin contributing, after deposition, to fibrosis (Kitada et al., 2013), a major 
characteristic of chronic kidney injury (Jadot et al., 2017b).  
Furthermore, SIRT1 was shown to be protective against oxidative stress, a process 
mediated, for example, by the deacetylation and activation of hypoxia-inducible factor-2 
alpha (HIF-2α), by the deacetylation of peroxisome proliferator-activated receptor γ 
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coactivator-1 alpha (PGC-1α) or by the activation of FOXOs factors. For example, they 
induce the antioxidative response triggered by catalase or superoxide dismutase 2 (SOD2) 
(Nogueiras et al., 2012). 
SIRT1 was also described as protective against inflammation. For example, SIRT1 
deacetylates the p65 subunit of the transcription factor NF-κB leading to its inhibition and a 
reduced expression of several pro-inflammatory genes encoding cytokines such as interleukin 
1 beta (IL-1β), interleukin 6 (IL-6) and tumour-necrosis factor alpha (TNF-α) (Kitada et al., 
2013).  
The human SIRT3 protein is found in both long and short isoforms and present in 
mitochondria (short isoform) or nuclei (long isoform). In addition, three isoforms of SIRT3 
were reported in mice; the first and the second one possess a nuclear localization while the 
third one is located into mitochondria (Cooper et al., 2009). These enzymes mainly regulate 
mitochondrial energy metabolism and redox status, more specifically in response to stress and 
are thus an adaptive regulator of several cells and mitochondrial responses (Nogueiras et al., 
2012). 
It is known that SIRT3 controls mitochondrial dynamics and degradation. Indeed, it 
inhibits the Drp1-dependent fission and by upregulation of OPA-1, by preventing the loss of 
membrane potential and PTEN-induced putative kinase 1–related (PINK1-related) mitophagy 
(Morigi et al., 2015; Perico et al., 2016). It allows a protection against mitochondrial 
fragmentation and cell death. SIRT3 also maintains basal ATP levels by a dual mechanism:  
1) prevention of excessive electron leakage and so oppose to the increase in ROS generation 
by the regulation of the function of the electron transport chain (ETC) complexes I and III;   
2) ROS detoxification by the activation of mitochondrial antioxidant enzymes (SOD2 or 
IDH2) (Benigni et al., 2016). Indeed, an elevated expression and activation of SIRT3 result in 
a reduction of oxidative stress following SOD2 activation by deacetylation. In addition, IDH2 
enzyme is activated by deacetylation. Its activation leads to the catalysis of isocitrate in         
α-ketoglutarate, producing NADPH, an important redox equivalent required for GSH 
regeneration from oxidized glutathione (GSSG) (Kincaid and Bossy-Wetzel, 2013). The 
SIRT3 activation induces an increase of GSH/GSSG ratio and so, a decrease of oxidative 
stress (Ouyang et al., 2019). 
These different roles of sirtuins 1 and 3 (SIRT 1 and 3), under oxidative stress or 
mitochondrial injury, are relevant. Indeed, accumulation of ROS and mitochondrial 
impairment were reported during AA-intoxication of rats, in particular in proximal tubular 
epithelial cells, the preferential cells targeted by AA (Figure 15) (Debelle et al., 2008; Galvan 
et al., 2017; Jadot et al., 2017b; Nortier et al., 2015). 
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Figure 15: Schematic illustration of putative roles of SIRT 1 and 3 in a context of oxidative stress, 
inflammation or fibrosis induced by AA. AAI, aristolochic acid I; CTGF, Connective tissue growth factor; 
ERK1/2, extracellular signal-regulated kinase 1/2; FOXOs, forkhead transcription factor; GSH, glutathione; 
IDH2, isocitrate dehydrogenase 2; IKKβ, subunit of IκB kinase; IL-6, interleukin-6; NF- κB, Nuclear factor-
kappa B; p, phosphorylated; PPM1A, phosphatase magnesium-dependent 1A; PTEN, Phosphatase and Tensin 
homolog; ROS, reactive oxygen species; SOD2, superoxide dismutase 2; TNF-α, Tumour-necrosis factor alpha. 
 
V. Cell line used in this master thesis 
We used HK-2 cells for experiments, which are proximal tubular cells from normal adult 
human kidney, immortalized by HPV-16 E6/E7 genes in order to retain relatively normal 
phenotypic expression. Due to the characteristics of primary proximal tubular cells (PTC) - 
inability to survive serial passages, variability amongst sequential PTC preparations and 
laborious isolation -, we chose HK-2 cells. Indeed, these cells display the same characteristics 
than PTC namely: 1) typical brush border membrane-associated enzymes, 2) recognition by 
antibodies directed against cytokeratin, vimentin, fibronectin and α3β1 integrin, 3) same 
functional characteristics of in vivo proximal tubules and primary PTC cultures,                     
4) maintenance in glucose-free medium, and 5) ability to ensure gluconeogenesis (Ryan et al., 
1994). These five features indicate a proximal tubular origin and phenotype, intact transport 
mechanisms and an ability to produce and store glycogen. HK-2 cells have also an           
EGF-dependent anchorage showing an immortalized cell line, besides the fact that these cells 
are a major advantage relative to animal or human embryonic-derived cell lines (Ryan et al., 
1994). 
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VI. Previous work 
Previous work in our laboratory (Mosseray, 2018) used toxic concentrations (10, 25, 50, 
75 and 100 µM) of AAI in vitro on HK-2 cells and in vivo on C57Bl/6 mice (3.5 mg/kg). 
Previous data has shown that AAI impairs renal function as demonstrated by an increase 
in proteinuria, a disorganization of the proximal tubular epithelial cells’ (PTEC) brush border 
or a necrosis of the proximal tubules in mice. In vivo, the expression of SIRT1 was reported as 
oscillating with a decrease after 12, 48, 96 h or 10 days whereas the expression of SIRT3 was 
decreased after 12 hours of exposure to AAI. 
In vitro, a concentration-dependent decrease in the cell viability was observed and the 
highly toxic concentration of 50 μM was chosen to study the toxic effect of AAI. In this 
previous work, mitochondrial fragmentation in HK-2 cells was observed (Figure 16). At that 
high concentration, preliminary data revealed that the relative mRNA expression of SIRT1 
was increased after 12 h of cell incubation with AAI while the relative mRNA abundance of 
SIRT3 was increased after 24 h of treatment.  
 
Figure 16: Mitochondrial morphology visualized by confocal microscopy on control cells (A) and cells 
incubated for 24 h with 50 μM of AAI (B). Aspect ratio (C) and ratio between end points and branched points 
(D). Data are expressed as means ± SEM, 30 cells analysed per group. Statistical analyses were performed 
using a t-Student test. *p≤0.05 vs control group. Pauline Mosseray data (Mosseray, 2018). 
However, the analysis of gene expression modifications in a context of cell toxicity and 
cell death is difficult and generated results which might be contaminated by confounding 
factors other than the effects of the molecule of interest.  
 
VII. Goal of the current work 
The main goal of this work is to study the putative role of sirtuins (SIRT) 1 and 3 (SIRT1 
and 3) in cytotoxicity induced by AAI. 
SIRT3 has already been studied in a model of sepsis-induced acute kidney injury (AKI) 
triggered by the ligation of the caecum at the colon juncture followed by puncturing or a 
lacing to the abdomen (Zhao et al., 2016). The authors highlighted that SIRT3 exerted 
protective effects against mitochondrial damage in the kidney as evidenced by a decrease in 
mitochondrial abundance and an increase in the mitochondrial permeability transition pore 
when the enzyme is less active (Zhao et al., 2016). In addition, the overexpression of SIRT3 
protected mice in a cisplatin-induced AKI model, a protective effect mediated by the 
enhancement of mitochondrial dynamics (Morigi et al., 2015). SIRT1 was also reported as 
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protective against oxidative stress triggered by ischemia-reperfusion in C57Bl/6 mice 
(Hasegawa et al., 2010). These different studies suggest protective effects of these sirtuins 
during AKI. However, sirtuins expression and activity in response to AA exposure as well as 
the mechanism triggered by these proteins to reduce cytotoxicity and nephrotoxicity remain 
poorly investigated. 
In this regard, the major objectives of the present study are: 1) to determine the optimal 
concentration and incubation time of HK-2 cells with AAI that are minimizing the toxicity,  
2) to measure the ATP content after AAI treatment and 3) to test an interferential approach 
using inhibitors and activators of SIRT1 and SIRT3 on the AAI-induced toxicity in HK-2 
cells. These experiments have been performed in order to test the modulation of enzyme 
activity on AAI-induced cell toxicity.  
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Material and methods 
 
I. Cell culture 
Human kidney-2 (HK-2) cells are proximal tubular epithelial cells obtained from normal 
adult human kidney, and immortalized by human papillomavirus-16 (HPV-16). HK-2 cells 
were obtained from American Type Cell Collection (ATCC CRL-2190TM, Belgium) and 
cultured in “Keratinocyte serum-free medium” (K-SFM/ThermoFisher Scientific, USA) 
supplied with bovine pituitary extract (BPE – 0.05 mg/mL) and human recombinant 
epidermal growth factor (EGF – 5 ng/mL) as recommended by manufacturer (Ryan et al., 
1994). For cell culture maintenance, cells were incubated in T75 culture flasks (75 cm
2
) 
(Corning-Costar®, USA) in a humidified atmosphere maintained at 37 °C and 5 % of CO2. 
When routinely cultured, cells were diluted 1:2 to obtain 80 % of cell culture confluence 
every three days. For the different experiments, cells were incubated in T25 culture flasks   
(25 cm
2
) (Corning-Costar®, USA) at the density of 1.25 x10
6
 cells/flask or in 24-well culture 
dishes (Corning-Costar®, USA) at the density of 100000 cells/well. 
 
II. Cell incubation with aristolochic acid I 
A stock solution of AAI was made by diluting AAI powder (Sigma-Aldrich, USA) in 
dimethylsulfoxide (DMSO, Sigma-Aldrich, USA) to obtain a concentration of 15 mM. To 
allow the solubilisation of AAI in DMSO, the solution was heated at 60 °C in a water bath for 
30 min, vortexed every 10 min and sterilized with a 0.2 µm Filtropur filter (Sarstedt, The 
Netherlands). The stock solution was stored at room temperature for one month and protected 
from light. Cells were incubated with freshly prepared sterile K-SFM media containing 
different concentrations of AAI (0.1, 0.25, 0.5, 0.75, 1, 2.5, 5, 7.5, 10, 20, 30, 40 or 50 µM). 
 
III. Cell viability assays 
a) Cell seeding 
HK-2 cells were seeded into 24-well culture dishes (Corning-Costar®, USA) at the 
density of 100000 cells/well. The next day and depending the experiment performed (as 
indicated in the legend of the figures), cells were incubated with fresh culture media 
containing AAI at 0, 0.1, 0.25, 0.5, 0.75 or 1 µM for 12, 24, 48 or 72 h (with or without 
medium change every 24 h), or at 0, 1, 2.5, 5, 7.5, 10 or 50 µM during 12, 24, 48 or 72 h. In 
several experiments, the concentration of 10 µM was used as a positive control able to induce 
toxicity. Then, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) and 
LDH (lactate dehydrogenase) assays were performed to assess cell viability/cytotoxicity. 
b) MTT assay 
The MTT assay was performed to assess cell viability (van Meerloo et al., 2011). This 
assay is based on the activity of the succinate dehydrogenase (SDH), a mitochondrial enzyme 
that catalyses the oxidation of succinate to fumarate in the Krebs/citric acid cycle in the 
mitochondrial matrix and transfers electrons to ubiquinone without pumping protons across 
the mitochondrial inner membrane (Huang and Millar, 2013). First, cells were seeded into  
24-well culture dishes (Corning-Costar®, USA) at the density of 100000 cells/well. Then 
cells were incubated with fresh culture media containing AAI at 0, 0.1, 0.25, 0.5, 0.75 or        
1 µM for 12, 24, 48 or 72 h (with or without medium change every 24 h). At the end of the 
incubation time, culture media were replaced by a PBS buffer containing MTT (Sigma-
19 
 
Aldrich, USA) diluted at 2.5 mg/mL mixed with K-SFM medium 1:1 (v:v) for a                      
2 h-incubation period at 37 °C in a humidified atmosphere. This step allows SDH of active 
metabolic cells to reduce MTT in formazan, forming purple crystals in aqueous medium. The 
MTT solution was then removed and 500 µL of lysis buffer (30 % sodium dodecyl sulfate 
(SDS), Fisher, USA, diluted in distilled water; N,N-dimethyl-formamide 2:1 (v:v), Rooth, 
France; pH 4.7) were added. Samples were placed on a rotary plate for 1 h at 37 °C. Finally, 
absorbance was measured at 570 nm in a spectrophotometer (xMark
TM
 Microplate, BioRad, 
Belgium) to determine the quantity of reduced MTT and thus, estimate cell viability.  
 
Figure 17: Principle of MTT assay and reaction catalysed by the SDH (Prakash, 2011). 
Results were calculated with the following formula: 
Cell viability (%) = 
(𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑒𝑠𝑡 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒−𝑏𝑙𝑎𝑛𝑘)
(𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒−𝑏𝑙𝑎𝑛𝑘)
 × 100 
In this work, the MTT assay was also used to assess cell proliferation and results were 
calculated with the following formula: 
Absorbance = 
(𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑒𝑠𝑡 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒−𝑏𝑙𝑎𝑛𝑘)
(𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒−𝑏𝑙𝑎𝑛𝑘)
 
The blank represents the measure of the lysis buffer absorbance and the control cell 
absorbance represent the measure of cells which are not treated with AAI. 
c) LDH assay 
A LDH assay was used to assess cytotoxicity of AAI by measuring the release of the 
intracellular enzyme LDH. An increase in LDH release is a marker of cell damage (defect of 
the integrity/permeability of the plasma membrane) (Abe and Matsuki, 2000; Allen et al., 
1994). In this assay, released LDH by damaged cells reduces NAD
+
 in NADH + H
+
. Then 
NADH reduces tetrazolium salt to formazan in the presence of electron coupling agents (Abe 
and Matsuki, 2000).  
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Figure 18: Principle of LDH assay (Cytotoxicity Detection Kit, Roche, USA). 
First, cells were seeded into 24-well culture dishes (Corning-Costar®, USA) at the 
density of 100000 cells/well. Then cells were incubated with fresh culture media containing 
AAI at 0, 0.1, 0.25, 0.5, 0.75 or 1 µM for 12, 24, 48 or 72 h (with or without medium change 
every 24 h). Positive control cells were obtained with cells incubated with PBS containing     
2 % Triton X-100 for 1 h in order to release the maximum of LDH. At the end of the 
incubation time, supernatants, or also named centrifuged conditioned-culture media, were 
collected and centrifuged for 5 min at 0.4 g. Next, a volume of 250 μL of PBS containing 2 % 
Triton X-100 was added for 10 min on the adherent cell monolayers (on agitation) (then 
called lysates) to permeabilize the cells. Conditioned-culture media and cell lysates were 
collected separately. Cell pellets, obtained after centrifugation (0.4 g) of cell conditioned-
culture media, were also lysed in 250 μL of PBS containing 2 % Triton X-100 for 10 min. 
Samples were placed into 96-well microplate (Greiner Bio-One, Germany) in the following 
way: 
- 100 μL of centrifuged conditioned-culture media, or 
- 100 μL of cell lysates recovered cell pellets, or 
- 5 μL of cell lysates and 95 μL of PBS containing 2 % Triton X-100, or 
- 100 μL of K-SFM medium (blank for conditioned-culture media from control 
cells), 
- 100 μL of K-SFM added each AA concentration (blank for conditioned culture 
media for AA-incubated cells), 
- 100 μL of PBS containing 2 % Triton X-100 (blank for cell pellets and cell 
lysates). 
Next, 100 μL of the reaction mixture (Cytotoxicity Detection Kit (LDH), Roche, USA) 
were added. Finally, the absorbance was measured in a spectrophotometer (xMark
TM
 
Microplate, BioRad, Belgium) (490 nm – sample – and 655 nm – reference –) every 5 min 
until values reach an absorbance between 2 and 3.  
Results were calculated using the following formula: 
Cytotoxicity (%) = 
((𝑙𝑦𝑠𝑎𝑡𝑒 𝑓𝑟𝑜𝑚 𝑐𝑒𝑙𝑙 𝑝𝑒𝑙𝑙𝑒𝑡−𝑏𝑙𝑎𝑛𝑘)+((𝑐𝑒𝑛𝑡𝑟𝑖𝑓𝑢𝑔𝑒𝑑 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑒𝑑−𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑚𝑒𝑑𝑖𝑎−𝑏𝑙𝑎𝑛𝑘)𝑥2))
(𝑙𝑦𝑠𝑎𝑡𝑒 𝑓𝑟𝑜𝑚 𝑐𝑒𝑙𝑙 𝑝𝑒𝑙𝑙𝑒𝑡−𝑏𝑙𝑎𝑛𝑘)+((𝑐𝑒𝑛𝑡𝑟𝑖𝑓𝑢𝑔𝑒𝑑 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑒𝑑−𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑚𝑒𝑑𝑖𝑎−𝑏𝑙𝑎𝑛𝑘)𝑥2)+((𝑐𝑒𝑙𝑙 𝑙𝑦𝑠𝑎𝑡𝑒 𝑓𝑟𝑜𝑚 𝑐𝑒𝑙𝑙 𝑚𝑜𝑛𝑜𝑙𝑎𝑦𝑒𝑟𝑠−𝑏𝑙𝑎𝑛𝑘)𝑥20)
𝑥100 
Factors 2 and 20 adjust the base formula as a result of the use of 250 μL de PBS 
containing 2 % Triton X-100. 
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IV. Protein assay by Folin-phenol reagent 
Briefly, in alkaline condition, the Folin reagent (phosphomolybdic phosphotungstic 
complex) is reduced by the phenolic ring of tyrosine residues of proteins. This reaction gives 
a blue coloration which allows a colorimetric assay. Cooper sulphate is added to make the 
reaction more sensitive and promote electron transfer (Lowry et al., 1951). HK-2 cells were 
seeded at a density of 10000, 25000, 50000, 75000 and 100000 cells/well in 24-well culture 
dishes (Corning-Costar®, USA) and were incubated for 6, 24, 48 or 72 h in a humidified 
atmosphere, 5 % CO2 and 37 °C. Cells were rinsed twice with 1 mL of PBS at room 
temperature. A volume of 200 μL of 0.5 N NaOH was added for 30 min. At the end of the 
alkaline hydrolysis, cell hydrolysates were collected for the protein assay. A calibration curve 
was done with known concentrations of Bovine Serum Albumin (BSA, ThermoFisher 
Scientific, USA) (0, 0.025, 0.05, 0.1 and 0.15 μg/μL). For the protein assay, 150 μL of 
hydrolysate were mixed with 750 μL of the solution A (2 % Na2CO3; 2 % sodium and 
potassium tartrate; 1 % CuSO4) for 10 min. Finally, 75 μL of Folin reagent (Merck, 
Germany), diluted twice in distilled water, were added every 30 s and samples were vortexed. 
At the end of a 30 min-incubation at room temperature, the absorbance was measured in a 
spectrophotometer (Ultrospec, Biochrom, England) at 740 nm. Protein assay was also used to 
monitor cell proliferation exposed at 0, 0.1, 0.25, 0.5, 0.75, 1 or 10 µM during 12, 24, 48 or 
72 h. For this experiment, HK-2 cells were seeded in 24-well culture plates (Corning-
Costar®, USA) at 100000 cells/well. 
Results were calculated using the following formula: 
𝑦 = 𝑎𝑥 + 𝑏 
 
V. ATP assay 
HK-2 cells were incubated with AAI solution freshly prepared and containing 0, 0.1, 0.5, 
1 or 50 µM for 24, 48 or 72 h, or containing 0, 1, 2.5, 5, 7.5, 10 or 50 µM for 3, 6, 12, 24 or 
48 h. Cells were also incubated with fresh culture medium containing 0, 1, 5, 10, 20, 30, 40 or 
50 µM during 24, 48 or 72 h, with or without medium change every 24 h to assess (even 
indirectly) the stability of the AAI, before ATP content was determined. 
First, cells were seeded into 24-well culture dishes (Corning-Costar®, USA) at a density 
of 100000 cells/well. The next day, culture media were replaced either by fresh K-SFM 
medium (control cells) or by K-SFM medium containing the different concentrations of AAI. 
At the end of the incubation period, cells were rinsed twice with sterile PBS. Then, 200 µL of 
“somatic cell ATP releasing reagent” (Sigma-Aldrich, USA) were added. After 10 s of 
incubation, solution was collected and placed in microtubes (4 °C). Cells were then rinsed 
with sterile PBS and 250 µL of 0.5 N NaOH were added for 30 min at room temperature. A 
protein assay was then done (Folin method as described in section IV) on cell proteins 
harvested to normalize the results of ATP content. For the ATP assay, samples were diluted 
100 times in distilled water and 100 µL of samples were mixed with 100 µL of ATP mixture. 
This mixture is composed of (a) reaction mixture, (b) luciferin buffer (2 mg/mL) and            
(c) luciferase buffer. The reaction mixture (a) was composed of 75 mM glycine, 75 mM 
Hepes; pH 7.7, 75 μM DTT (dithiothreitol), 125 μM EDTA and 6.25 mM MgCl2. The 
luciferin buffer (b) was composed of 25 mM Tris; pH 7.75, 125 μM EDTA, 75 μM DTT,  
6.25 mM MgCl2 and luciferin. The luciferase buffer (c) was composed of 0.5 M glycine;     
pH 7.7, and luciferase. The reaction (Figure 19) catalysed by the luciferase produces photons 
that are measured with a luminometer (Lucetta
TM
 Luminometer, Lonza, USA). 
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Figure 19: Reaction produced by the assay. Bioluminescence is emitted from the reaction of luciferase enzyme 
and its substrate, firefly luciferase and luciferin, respectively. Co-substrates are ATP and O2. ATP is hydrolysed 
and light is emitted when firefly luciferase catalyses the oxidation. 
 
VI. Activation or inhibition of SIRT1 and SIRT3 
Before inducing either the activation or the inhibition of SIRT1 and SIRT3, the toxicity 
of each activator or inhibitor (see Figure 20) has been tested by MTT and LDH assays (as 
described in section III). Cells were seeded at a density of 100000 cells/well. When 80 % of 
confluence were reached, cells have been incubated for 24, 48 or 72 h with EX527 (Santa 
Cruz Biotechnology, USA), SRT2104 (Selleckchem, USA), 3-TYP (Selleckchem, USA) or  
7-hydroxy-3-(4'-methoxyphenyl) Coumarin (Synquest Laboratories, USA) at different 
concentrations. 
 Inhibitor Activator 
SIRT1 
 
 
EX527 
 
 
SRT2104 
SIRT3 
 
 
3-TYP 
 
 
7-hydroxy-3-(4'-methoxyphenyl) 
Coumarin 
Figure 20: List of inhibitors and activators of SIRT1 and SIRT3 used in this investigation. 
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The optimal concentration of each activator or inhibitor was then chosen for 
concentrations that were not toxic based on the assays performed. HK-2 cells were seeded in 
T25 culture dishes (Corning-Costar®, USA) and, 24 h later, cell culture media were replaced 
by fresh K-SFM medium (control cells) or by fresh K-SFM medium containing activators or 
inhibitors. The following concentrations were used: 10 µM of EX527, 3-TYP and 7-hydroxy-
3-(4'-methoxyphenyl) Coumarin and 25 µM of SRT2104. After a pre-incubation of the cells 
for 3 h with the inhibitor of sirtuins (EX527 or 3-TYP) for SIRT1 or SIRT3, respectively, 
cells were incubated with media containing 1 µM of AAI in the presence of the sirtuin 1 or 3 
inhibitor. After a pre-incubation of the cells for 3 h with the activator of sirtuins (SRT2104 or 
7-hydroxy-3-(4'-methoxyphenyl) Coumarin) for SIRT1 or SIRT3, respectively, cells were 
incubated with media containing 10 or 50 µM of AAI in the presence of the sirtuin 1 or 3 
activator. Cells were then incubated for 24, 48 or 72 h and media were changed every 24 h. At 
the end of the incubation period, cell lysates were prepared as described in section VIII and 
samples were prepared for western blot analysis. In addition, MTT and LDH assays were 
performed, as described in section III. 
 
VII. RT-qPCR 
RT-qPCR allows to quantify the relative expression of a gene. The expression of SIRT1 
and SIRT3 genes was quantified in HK-2 cells incubated with different concentrations of AAI. 
The 18S gene, coding for rRNA, was used as a housekeeping gene due to its constant 
expression level in these experimental conditions. HK-2 cells were seeded in T25 culture 
dishes (Corning-Costar®, USA) and 24 h later, cell culture media were replaced by fresh     
K-SFM medium (control cells) or by fresh K-SFM medium containing 0, 0.1, 0.5, 1, 10, 30 or 
50 µM of AAI. Cells were then incubated for 24, 48 or 72 h in a humidified atmosphere 
containing 5 % of CO2 and at 37 °C.  
a) RNA extraction 
This step was performed in “RNAse-free” conditions. At the end of the incubation period, 
the conditioned culture media were replaced by 500 µL of Lysis buffer (LBA)-thioglycerol 
(Promega, USA) and cell lysates were then collected in microtubes. A volume of 170 µL of 
isopropanol was added to provide ideal binding conditions and the mixture was homogenized. 
Then, 400 µL of lysate/isopropanol were collected and poured on a column placed on a 
collection tube (Promega, USA) and centrifuged for 30 s at 12000 g. The remaining sample 
was then poured on the same column and also centrifuged for 30 s at 12000 g. Next, 500 μL 
of RNA wash solution (RWA) were added in order to rinse membrane-bound RNA and 
sample was centrifuged for 30 s at 12000 g. A mixture containing 3 μL of DNAse I enzyme 
(Promega, USA), 24 µL of yellow core buffer (Promega, USA) and 3 μL of 0.09 M MnCl2 
(Promega, USA) was prepared to remove residual amounts of DNA. A volume of 30 μL of 
this mixture was poured on the column for 15 min at room temperature. Afterwards, 200 μL 
of column wash solution (CWE) were added and centrifuged for 15 s at 12000 g. The column 
was then rinsed with 500 μL of RWA, diluted in ethanol, and centrifuged for 15 s at 12000 g. 
A volume of 300 μL of RWA was added and centrifuged for 2 min at 12000 g. Finally, the 
column was placed in a microtube of 1.5 mL and 50 μL of RNAse-free water were added, to 
elute RNA. This final product was centrifuged for 1 min at 12000 g. Measurement of RNA 
concentration was performed with a Nanodrop 1000 spectrophotometer (Isogen Life Science, 
The Netherlands). RNA was finally stored at –80 °C in microtubes until use. 
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b) Reverse transcription 
Following the manufacturer’s instructions (GoScriptTM Reverse Transcriptase, Promega, 
USA) and to obtain cDNA, 2 μg of RNA were diluted in RNAse-free water up to a volume of 
12 μL and the samples were incubated for 5 min at 70 °C to denature RNA (Promega, USA). 
Then, a volume of 8 μL of the reaction mixture (Buffer Mix Random Primer; Enzyme mix; 
RNA
se
-free water) (Promega, USA) was added and samples were then successively incubated 
for 5 min at 25 °C (primers hybridization), for 60 min at 42 °C (cDNA extension) and for     
15 min at 70 °C (enzyme inactivation). Finally, cDNA was stored at –20 °C in microtubes 
until use. 
c) qPCR 
For the qPCR in real time, a mixture, composed of 10 μL of SyberGreen (GoTaq® qPCR 
Master Mix, Promega, USA) and 5 μL of forward and reverse primers (Figure 21), was 
loaded in a 96-well plate (ThermoFisher Scientific, USA) and combined with 5 μL of cDNA. 
Finally, the plate was centrifuged for 1 min at 12000 g and inserted in the Step One Plus
TM
 
Real-Time PCR System (ThermoFisher Scientific, USA). The amplification was followed 
during 40 cycles: 15 s at 95 °C, 10 s at 60 °C, and 20 s at 72 °C.  
Results were analysed by 2
-ΔΔCt
 method (Bustin et al., 2009), using the following 
formula: 
1) ∆𝐶𝑡 = 𝐶𝑡 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 −  𝐶𝑡 ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒 
2) ∆∆𝐶𝑡 =  ∆𝐶𝑡 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 − ∆𝐶𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑜𝑓 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 
3) 2−∆∆𝐶𝑡 
Gene Direction Primer sequence (5’  3’) 
SIRT1 
Forward TAGCCTTGTCAGATAAGGAAGGA 
Reverse ACAGCTTCACAGTCAACTTT 
SIRT3 
Forward TCACTACTTTCTCCGGCTG 
Reverse CAATGTCGGGCTTCACAACG 
18S 
Forward TGGTGCATGGCCGTTCT 
Reverse TAGTTAGCATGCCAGAGTCTCGTT 
Figure 21: List of target genes and primer sequences used. 
 
VIII. Western blot analysis 
HK-2 cells were seeded in T25 culture dishes (Corning-Costar®, USA) and 24 h later, 
cell culture media were replaced by fresh K-SFM medium (control cells) or by fresh K-SFM 
medium containing 0, 0.1, 0.5, 1, 10 or 30 µM of AAI. Cells were then incubated for 24, 48 or 
72 h in a humidified atmosphere containing 5 % of CO2 and at 37 °C. At the end of the 
incubation period, cells were rinsed with PBS (4 °C). A volume of 200 µL of “DLA” lysis 
buffer (7 M urea, Merck, Germany; 2 M thiourea, Sigma-Aldrich, USA; 1 % CHAPS, Sigma-
Aldrich, USA; 1 % ASB14, Sigma-Aldrich, USA; Tris 30 mM, Invitrogen, USA; pH 8.5; 1 % 
SDS, Panreac, Spain) containing PIB (phosphatase inhibitor buffer: 120 mM NaF, Merck, 
Germany; 250 mM β-glycerophosphate, VWR, Belgium; 25 mM Na3VO4, Sigma-Aldrich, 
USA; 250 mM 4-nitrophenylphosphate Sigma-Aldrich, USA) and PIC (protease inhibitor 
cocktail, [Roche, Switzerland]) was added. Cell lysates were collected with a scraper and 
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poured in microtubes. Cell lysates were then homogenized during 30 min in a 12 °C-
ThermoMixer (under 4 °C, SDS precipitates and behind 25 °C, urea forms cyanates) and 
centrifuged for 10 min at 14000 g. Finally, supernatants were collected and stored at -80 °C. 
a) Protein content determination 
The total amount of proteins was determined in each sample by Pierce
TM
 660 nm reactive 
(ThermoFisher Scientific, USA), which contains a colorant-ion complex having the property 
to bind to basic amino acids of proteins. The colorant deprotonation in acidic conditions 
induces a coloration change from orange to green and a change in the maximal absorption of 
the colorant. In addition to the Pierce
TM
 660 nm reactive, the Ionic Detergent Compatibility 
Reagent (IDCR - ThermoFisher Scientific, USA) was added (1 g/20 mL of Pierce). After       
5 min of incubation at room temperature, when the reaction was stabilized, absorbance was 
read at 660 nm in a spectrophotometer xMark
TM
 Microplate (Biorad, Belgium). A calibration 
curve was realized with standard samples of known BSA concentration (0, 0.025, 0.125, 0.25, 
0.5, 0.75, 1 and 1.5 µg/µL) (ThermoFisher Scientific, USA) which allows the determination 
of the protein concentration of each sample. 
b) Preparation of samples 
Based on established protocols (Biorad, Belgium), samples were diluted in distilled water 
to obtain a total of 12 µg of proteins for SIRT1, 10 to 15 μg of proteins for SIRT3 and 14 µg 
of proteins for (Ac-)SOD2 and H3(K9) in a volume of 20 µL for the immunodetection 
analysis. A volume of 5 μL of loading blue (143 mM Tris-HCl; pH 6.8; 20 % SDS; 2 M        
β-mercaptoethanol; 25 % glycerol and 0.75 mM blue of bromophenol) was added to samples 
to denature the proteins, burden samples and visualize the migration front. Then, samples 
were heated for 5 min at 100 °C to denature proteins and then centrifuged 2 min at 13000 g. 
Finally, 20 μL of each sample were loaded in a homemade polyacrylamide gel (see section 
VIII.c.). The marker lane was filled with 2.5 μL of ladder (Color Protein Standard, Broad 
Range (11-245 kDa), Bioké, UK) composed of 20 mM Tris-phosphate; pH 7.5, 2 % SDS,   
0.2 mM DTT, 3.6 M urea and 15 % glycerol. 
c) Migration 
The migration gel is composed of two parts: the stacking gel allowing the concentration 
of proteins at the entry of the running gel and the running gel allowing the 
separation/resolution of proteins according to their molecular weight. Gels are composed of 
1.5 M Tris-HCl; pH 8.8, Temed (Rooth, France), 30 % acrylamide (BioRad, Belgium), 10 % 
APS (BioRad, Belgium), 10 % SDS (Sigma-Aldrich, USA) and distilled water. Quantities of 
these compounds vary according to the gel type and the percentages (12 and 3.75 % in this 
work). Gels were casted between 2 glass plates (Bio-Rad, USA) and a comb of 0.75 mm was 
put in the stacking gel to form wells where samples were disposed. Then, gel was disposed in 
a tank filled with migration buffer (0.25 M Tris Base, Rooth, France; pH 8.5; 1.92 M glycine, 
Rooth, France; 20 % SDS, Sigma-Aldrich, USA; distilled water). The electrophoretic protein 
resolution was performed at 150 V for 45 min. 
d) Transfer 
Proteins were transferred on a polyvinylidene fluoride (PVDF, Bio-Rad, USA) 
membrane. The membrane was activated for 1 min in methanol and rinsed with transfer buffer 
(5x Transfer Buffer - composition fixed by the firm BioRad, Belgium -; Ethanol, Univars, 
Belgium; distilled water). The activated membrane and gel were sandwiched between 2 
transfer stacks (Bio-Rad, USA) dipped in transfer buffer and placed at room temperature in 
the Trans-Blot® Turbo™. A constant amperage current (1.3 A) was applied during 7 min to 
allow the migration of the proteins from the gel to the PVDF membrane.  
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e) Immunodetection  
The membrane was placed in a solution containing PBS and Odyssey Blocking Buffer 
PBS, dilution 1:1, (LI-COR, USA) for 1 h in order to allow the saturation of unspecific 
antigenic sites of the membrane and thus to reduce the background. The membranes were then 
incubated for 16 h at 4 °C with primary antibody (Figure 22) diluted in Odyssey Blocking 
Buffer PBS (LI-COR, USA)-0.1 % Tween 20 (BioRad, Belgium). At the end of the 
incubation, the membrane was rinsed 3 times for 5 min with PBS-0.1 % Tween 20 (BioRad, 
Belgium) and then incubated for 1 h at room temperature with secondary antibodies coupled 
with a fluorochrome (Figure 22). Then, membranes were rinsed 3 times during 5 min with  
0.1 % PBS-Tween 20 (BioRad, Belgium) and twice with PBS. The membrane was then dried 
during 30 min in an incubator at 37 °C. Proteins were visualized with Odyssey® imaging 
system (LI-COR, USA) either at 800 nm or at 700 nm (Figure 22). Finally, fluorescence of 
each band was quantified with the software Image Studio™ Lite Version 5.2 (LI-COR, USA). 
For the quantification, the fluorescence of the signals of interest was then normalized for the 
fluorescence of the α-Tubulin signals:  
Protein relative abundance = 
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑠𝑖𝑔𝑛𝑎𝑙𝑠 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑠𝑖𝑔𝑛𝑎𝑙𝑠 𝑜𝑓 𝛼−𝑇𝑢𝑏𝑢𝑙𝑖𝑛
 
 
Primary 
antibody 
 Reference Secondary 
antibody 
Molecular 
weight 
Anti-Sirtuin 3 
Rabbit 1:2000 
16 h 4 °C (Cell 
Signaling, 
USA) 
5490S Goat anti-
rabbit 800 nm 
1:10000 1 h 
RT (LI-COR, 
USA) 
28 kDa 
Anti-Sirtuin 1 
Mouse 1:500 
16 h 4 °C (Cell 
Signaling, 
USA) 
8469S Goat anti-
mouse 700 nm 
1:10000 1 h 
RT (LI-COR, 
USA) 
120 kDa 
Anti-SOD2 
Rabbit 1:2000 
16 h 4 °C 
(Merck, 
Germany) 
06-984 Goat anti-
rabbit 800 nm 
1:10000 1 h 
RT (LI-COR, 
USA)  
24 kDa 
Anti-Ac-SOD2 
Rabbit 1:2000 
16 h 4 °C 
(Abcam, UK) 
ab137037 Goat anti-
rabbit 800 nm 
1:10000 1 h 
RT (LI-COR, 
USA)  
24 kDa 
Anti-Histone 
H3 Rabbit 
1:2000 16 h 4 
°C (Cell 
Signaling, 
USA) 
4499S Goat anti-
rabbit 800 nm 
1:10000 1 h 
RT (LI-COR, 
USA) 
17 kDa 
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Anti-Ac-
Histone H3 
(Lys9) Rabbit 
1:1000 16 h 4 
°C (Merck, 
Germany) 
06-942 Goat anti-
rabbit 800 nm 
1:10000 1 h 
RT (LI-COR, 
USA) 
17 kDa 
Anti-α-Tubulin 
Mouse 1:10000 
30 min RT 
(Sigma-
Aldrich, USA) 
T5168 Goat anti-
mouse 700 nm 
1:10000  30 
min RT (LI-
COR, USA) 
50 kDa 
Figure 22: List of primary and secondary antibodies used in this work. 
 
IX. Statistical analysis  
All data are expressed as mean ± SEM (standard error of the mean). For all statistical 
analyses, analysis of variance I (one-way ANOVA) and a Dunnett test were performed to 
compare results (GraphPad Prism, version 5.04). Differences between means with a p-value 
of 0.05 were considered as significantly different. 
  
 
 
Figure 23: Effects of cell density on HK-2 cell proliferation over time. Cells were seeded at different densities 
in 24-well culture dishes and were then incubated for 6, 24, 48 and 72 h. At the end of the incubation periods, 
protein content associated with cell monolayers was determined by Folin assay. Results are expressed in total 
amount of proteins as means for 3 technical replicates (n=1, three wells analysed). 
 
 
 
Figure 24: Effects of AAI on HK-2 cell viability assessed by MTT assay. Cells were seeded at 100000 
cells/well in 24-well culture dishes and incubated in the presence of 0, 0.1, 0.25, 0.5, 0.75 or 1 μM of AAI for 12, 
24, 48 or 72 h. Results are expressed as means of the percentages of viability compared to control (fixed 
arbitrarily at 100 % for each control time-point) for three wells (n=1). 
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Results   
 
I. Effects of cell density on HK-2 cell proliferation 
First, it was necessary to determine the cell density for the seeding of HK-2 cells that is 
compatible with incubation periods of several days, knowing that the reported doubling time 
for these cells is about 36 h (Iwata and Zager, 1996). On the one hand, the conduct of the 
experiment requires getting as much material as possible to allow the different read outs 
(RNA extraction, western blot analysis …). On the other hand, we did not want that the cells 
reach “contact inhibition” or start to suffer from a too high cell density leading to cell stress 
related to culture conditions. Indeed, cell density could be a confounding factor when the 
toxicity of AAI is analysed. As presented in Figure 23, protein contents are proportional to 
cell density seeded. Moreover, no slowing or stop of cell proliferation was observed during 
the first 72 h in culture, no matter what the cell density tested even at the highest cell density 
(100000 cells/well). Cell micrographs corresponding to this experiment are presented in 
annexe I (Figure 46). 
Based on these results, showing that cell proliferation rate increases with cell density up 
to 72 h of incubation, a cell density of 100000 cells/well of a 24-plate format was chosen for 
future experiments, because it allows to get enough of cell material for the analysis without a 
noticeable alteration of cell proliferation index.  
 
II. Effects of different AAI concentrations on HK-2 cell viability 
Our first objective was to determine the optimal conditions to allow the study of SIRT1 
and SIRT3 expression/abundance in cells exposed to AAI without important cell death. AAI 
toxicity on HK-2 cells was first determined by MTT assay. Preliminary data revealed that 
high concentrations such as 10 and 50 µM were highly toxic for cells (Mosseray, 2018). Cells 
were then voluntary incubated with low concentrations of AAI (0, 0.1, 0.25, 0.5, 0.75 or         
1 µM) for 12, 24, 48 or 72 h. Indeed, the analysis of the expression of a gene of interest in 
dying cells is always difficult as one can never be sure that the abundance of the gene product 
analysed revealed the effect of the tested molecule or results from the modifications in gene 
expression of passenger genes associated with cell death. As observed in Figure 24, AAI does 
not induce toxicity of HK-2 cells at low concentrations tested. In addition, a representation of 
the effect of low concentrations of AAI on cell proliferation of HK-2 cells is presented in 
annexe II (Figure 47). 
 
   
Figure 25: Effects of low AAI concentrations on HK-2 cell cytotoxicity as assessed by LDH assay. Cells were 
seeded at 100000 cells/well in 24-well culture dishes and incubated in the presence or in the absence (CTL) of 
AAI at different concentrations (0.1, 0.25, 0.5, 0.75 or 1 μM) for 12, 24, 48 or 72 h. Results are expressed as 
means of percentages of cytotoxicity for three wells (n=1). 
 
Figure 26: Effects of a higher concentration of AAI on HK-2 cell viability as assessed by MTT assay. Cells 
were seeded at 100000 cells/well in 24-well culture dishes and incubated in the presence or in the absence 
(CTL) of 10 μM of AAI for 12, 24, 48 or 72 h. Results are expressed as means of percentages of viability 
compared to control (fixed arbitrarily at 100 % for each control time-point) for three wells (n=1). 
 
Figure 27: Effects of a higher AAI concentration on HK-2 cell cytotoxicity as assessed by LDH assay. Cells 
were seeded at 100000 cells/well in 24-well culture dishes and incubated in the presence of 0 or 10 μM of AAI 
for 12, 24, 48 or 72 h. Results are expressed as means of percentages of cytotoxicity for three wells (n=1). 
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To confirm these results, cell toxicity of AAI was assessed by a LDH assay. HK-2 cells 
were incubated in the presence or in the absence (CTL) of 0.1, 0.25, 0.5, 0.75 or 1 µM of AAI 
for 12, 24, 48 or 72 h (Figure 25). There is no difference in cytotoxicity observed, whatever 
the concentration or incubation time tested. The positive control represents the maximal 
release of LDH in control cells incubated in the absence of AAI for different periods of time 
and permeabilized with Triton X-100.  
These results on toxicity of low AAI concentrations were next compared to toxicity 
induced by a higher concentration (10 µM), known to be toxic (Yang et al., 2010). As shown 
in Figure 26, at the AAI concentration of 10 μM, a time-dependent decrease in cell viability is 
observed when this parameter is assessed by a MTT assay. An increase in the cytotoxicity, 
assessed by LDH activity release, was also observed in cells incubated in the presence of     
10 μM AAI for 24, 48 or 72 h (Figure 27). 
 
  
 
 
Figure 28: Effects of different AAI concentrations on HK-2 cell proliferation. Cells were seeded at 100000 
cells/well in 24-well culture dishes and incubated in the presence or in the absence (CTL) of different 
concentrations of AAI (0.1, 0.25, 0.5, 0.75, 1 or 10 µM) for 12, 24, 48 or 72 h. At the end of the different 
incubation periods, protein content associated with cell monolayers was determined by Folin assay. Results are 
expressed in total amount of proteins and represent means for three wells (n=1). 
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III. Effects of different AAI concentrations on HK-2 cell proliferation 
We next addressed the question to know whether low and non-toxic concentrations of 
AAI are able to affect cell proliferation or not. Cells were incubated with or without different 
concentrations of AAI during 12, 24, 48 or 72 h before the determination of protein content. 
As observed in Figure 28, low concentrations of AAI do not strongly affect proliferation of 
cells even if, at 1 µM, a slight reduction of cell proliferation is observed between 48 and 72 h 
of incubation. Moreover, a concentration of 10 µM of AAI is toxic (as observed by the 
reduced amount of proteins obtained after a cell incubation of 12 h) and impairs cell 
proliferation. For this concentration, toxicity was observed by MTT and LDH assay (Figure 
26 and 27, respectively). However, the analysis of cell proliferation by a protein assay cannot 
discriminate between the alteration of cell cycle/cell proliferation and toxicity. 
 
  
Figure 29: Effects of low AAI concentrations on cellular ATP content. Cells were seeded at 100000 cells/well 
in 24-well culture dishes and incubated with or without (CTL) different concentrations of AAI (0.1, 0.5, or 1 µM) 
for 24, 48 or 72 h. Results are expressed in percentages of ATP content compared to the arbitrarily fixed values 
of 100 % for control cells at each experimental time-point; ATP content is normalised by protein content of each 
well. Results are expressed as means ± SEM for n=4. Statistical analysis was performed by one-way ANOVA 
followed by Dunnett post-test. 
 
Figure 30: Effects of a high concentration of AAI on cellular ATP content. Cells were seeded at 100000 
cells/well in 24-well culture dishes and incubated with or without 50 µM of AAI for 24, 48 or 72 h. Results are 
expressed in percentages of ATP content compared to the arbitrarily fixed values of 100 % for control cells at 
each experimental time-point; ATP content is normalised by protein content of each well. Results are expressed 
as means ± SEM for n=4. Statistical analysis was performed by one-way ANOVA followed by Dunnett post-test. 
 
Figure 31: Effects of different AAI concentrations on cellular ATP content. Cells were seeded at 100000 
cells/well in 24-well culture dishes and incubated in the presence or in the absence (CTL) of AAI at different 
concentrations (1, 5, 10, 20, 30, 40 or 50 µM) for 24, 48 or 72 h. Results are expressed in percentages of ATP 
content compared to the arbitrarily fixed value of 100 % for control cells at each experimental time-point. 
Results are expressed as means (bar) for duplicates (n=2).
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IV. Effects of different AAI concentrations on cellular ATP content  
Previous work in our laboratory revealed that cells incubated during 24 h in the presence 
of 50 μM of AAI display a mitochondrial fragmentation (as explained in the introduction, 
section VI).  
As mitochondrial fragmentation observed in cells exposed to a toxic AAI concentration 
might be accompanied by ATP production alterations, in this work, an ATP assay was used to 
assess ATP contents in cells exposed to AAI (Figures 29 and 30). While there is no major 
change in ATP contents for cells incubated with concentrations up to 1 μM (Figure 29), a 
time-dependent decrease in ATP contents is observed in cells exposed to 50 μΜ of AAI 
during 24, 48 or 72 h (Figure 30). This decrease is thus correlated to mitochondrial 
fragmentation observed in cells incubated with 50 μM during 24 h, suggesting that changes in 
mitochondria dynamics and fragmentation are associated with alterations of mitochondrial 
ATP production.  
To cover the range between the highest concentration used in this work (1 µM) and the 
concentration used by P. Mosseray (50 µM), an ATP assay was performed on cells incubated 
in the presence of 0, 1, 5, 10, 20, 30, 40 or 50 µM of AAI for 24, 48 or 72 h. A time- and 
concentration-dependent decrease in ATP contents is observed for cells incubated with 10 µM 
and higher concentrations for 48 and 72 h (Figure 31). 
Additionally, the concentration range between 1 and 10 µM in AAI and shorter 
incubation times have been tested in order to assess the cytotoxicity of the molecule. 
However, no alteration of ATP contents was observed in cells incubated for 3, 6, 12, 24 or   
48 h in the presence of 0, 1, 2.5, 5, 7.5, 10 or 50 µM of AAI, when compared to the ATP 
contents in control cells, except at 50 µm for 48 h (data not shown). 
 
 
 
 
 
 
  
  
Figure 32: Effects of AAI on the relative mRNA abundance of SIRT1 (A) or SIRT3 (B). Cells were seeded at 
1.25x10
6
 cells/T25 culture dishes and incubated in the presence or in the absence (CTL) of different AAI 
concentrations (0.1, 0.5, 1 or 10 µM) for 24, 48 or 72 h (n=4 for CTL, 0.1, 0.5 and 1 µM conditions, 2 wells per 
condition; n=3 for 10 µM condition, 2 wells per condition). Results are expressed as relative mRNA abundance 
for SIRT1 (A) or SIRT3 (B) and represent as means ± SEM. Statistical analysis was performed by one-way 
ANOVA followed by Dunnett post-test. AA vs CTL conditions: **: p< 0.01; ***: p< 0.001; NS, Non-
Significantly different when compared to CTL. 
 
Figure 33: Effects of AAI on the relative abundance of SIRT1 (A) and SIRT3 (B) enzymes. Cells were seeded 
at 1.25x10
6
 cells/T25 culture dishes and incubated in the presence or in the absence (CTL) of AAI at different 
concentrations (0.1, 0.5, 1 or 10 µM) for 24, 48 or 72 h (n=1 for SIRT1; n=3 for SIRT3). For western blot 
analysis of SIRT1, 12 μg of proteins were loaded (A). For SIRT3 western blot, 12 μg of proteins were loaded (B). 
Results are expressed as protein relative abundance and normalised by ɑ-tubulin used as a loading control. 
Statistical analysis was performed by one-way ANOVA, followed by Dunnett post-test. AAI-treated cells vs 
control cells: NS, Non-Significant. 
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V. Effects of AAI on sirtuins 1 and 3 abundance 
Previous work in our laboratory reported that the relative mRNA abundance of SIRT1 is 
significantly increased in cells exposed to 50 μM during 12 or 24 h and that the relative 
protein abundance of SIRT1 is significantly increased at 24 h (data not shown (Mosseray, 
2018)). Moreover, it is also known that the relative mRNA abundance of SIRT3 is 
significantly decreased in cells incubated in the presence of AAI at 50 µM during 6 h, but 
significantly increased at 24 h. Strikingly, no significant difference was found for the protein 
abundance of SIRT3 in cells exposed to 50 µM of AAI, no matter what the time of incubation 
considered (data not shown (Mosseray, 2018)). 
To evaluate the putative effects of low concentrations of AAI on the abundance of SIRT1 
and SIRT3, the relative expression of these sirtuins was evaluated at both mRNA (Figure 32) 
and protein (Figure 33) levels. As shown in Figure 32 A, the relative mRNA abundance of 
SIRT1 remains stable for subtoxic concentrations, but is increased in cells exposed to AAI at 
10 μM for 24, 48 or 72 h. For SIRT3, AAI does not have any effect on the mRNA abundance 
in cells incubated either in the presence of low AAI concentrations or in the presence of the 
toxic 10 µM concentration (Figure 32 B).  
As shown in Figure 33, few changes in the abundance of SIRT1 at the protein level are 
observed in cells exposed to 0, 0.1, 0.5 or 1 μM AAI for 24, 48 or 72 h, and a slight increase 
in the 10 µM condition, for 48 or 72 h, is also observed. For SIRT3, a non-significant 
decrease of its abundance is observed in cells incubated for 72 h with 10 µM of AAI. 
 
  
 
 
Figure 34: Effects of Coumarin on the abundance of Ac-SOD2 (A for 24 h and B for 48 and 72 h). Cells were 
seeded at 1.25x10
6
 cells/T25 dishes and incubated in the presence (CTL + Coumarin) or in the absence (CTL) of 
Coumarin and in the presence of 50 μM of AAI (50 µM) with (50 µM + Coumarin) or without (50 µM) 
additional 10 µM of Coumarin  for 24 h (A). For 48 or 72 h (B), cells were incubated in the presence (CTL + 
Coumarin) or in the absence (CTL) of Coumarin and in the presence of 10 µM of AAI (10 µM) with (10 µM + 
Coumarin) or without (10 µM) additional 10 µM of Coumarin (n=1). For this western blot analysis, 14 μg of 
proteins were loaded in the gel. Results are expressed as protein relative abundance and normalised by             
ɑ-tubulin used as a loading control.  
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VI. Effects of sirtuins 1 and 3 activators or inhibitors on acetylated targets of both 
enzymes, cytotoxicity and cell proliferation  
As mentioned, four molecules (Coumarin, 3-TYP, SRT2104 and EX527) were tested, in 
order to evaluate a putative sensitisation of sirtuins inhibitors (3-TYP and EX527) or a 
potential protection of sirtuins activators (Coumarin and SRT2104) against the AAI-induced 
toxicity for HK-2 cells, respectively with a concentration of 1 or 10 and 50 µM. They are the 
topics of the following developments. 
For the experiments evaluating the putative protection, two concentrations of AAI have 
been used: 10 and 50 µM. The concentration of 10 µM was used for long time period and the 
concentration of 50 µM was used for short time period. Indeed, 50 µM is too toxic to keep 
enough material until 72 h-incubation. 
 
The first tested molecule was the Coumarin, an activator of SIRT3 activity.  
a) Effects of Coumarin on the acetylation status of SOD2, a sirtuin 3 target 
As observed in Figure 34 A, there is a slight decrease in the SOD2 acetylation in cells 
incubated for 24 h with 10 µM of Coumarin, when compared to control cells. At 24 h, we do 
not see any modification of SOD2 acetylation in cells exposed to 50 µM of AAI and the 
presence of Coumarin does not affect the acetylation level of the antioxidant enzyme (Figure 
34 A). 
However, surprisingly, for 48 h of incubation, we observed an increase in the acetylation 
status of SOD2 (Figure 34 B). In addition, in cells incubated with 10 µM of AAI alone, the 
acetylation of the antioxidant enzyme is also increased and this acetylation is prevented in 
cells incubated for 48 h with 10 µM of AAI and 10 µM of Coumarin (Figure 34 B).  
For 72 h-incubation, we still observed an increase in SOD2 acetylation in cells incubated 
with 10 µM of AAI, but the presence of Coumarin does not change the acetylation level of the 
enzyme (Figure 34 B). 
 
  
 
 
Figure 35: Effect of Coumarin on HK-2 cytotoxicity in the presence or in the absence of high concentration 
of AAI as assessed by LDH (A for 24 h; B for 48 or 72 h) assay. Cells were seeded at 100000 cells/well in     
24-well culture dishes and incubated in the presence or in the absence (CTL) of 50 μM of AAI for 24 h (A) or in 
the presence or in the absence (CTL) of 10 µM of AAI for 48 or 72 h (B). As indicated, in some conditions,       
10 µM of Coumarin were added to cells for the same period of time. Results are expressed as means of 
percentages of cytotoxicity for three wells (n=1). 
 
 
 
Figure 36: Effect of Coumarin on HK-2 cell proliferation in the presence or in the absence of high 
concentration of AAI as assessed by MTT (A for 24 h; B for 48 or 72 h) assay. Cells were seeded at 100000 
cells/well in 24-well culture dishes and incubated in the presence or in the absence (CTL) of 50 μM of AAI for  
24 h (A) or in the presence or in the absence (CTL) of 10 µM of AAI for 48 or 72 h (B). As indicated, in some 
conditions, 10 µM of Coumarin were added to cells for the same period of time. Results are expressed as 
absorbance unit and represent means of absorbance for three wells (n=1). 
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b) Effects of Coumarin, an activator of SIRT3, on cell toxicity and proliferation 
Regarding the cytotoxicity, Coumarin does not reduce the toxicity of AAI for HK-2 cells 
(Figure 35 A and 35 B), when compared to the toxicity induced by 10 or 50 µM of AAI. In 
addition, there is no toxicity of Coumarin alone on HK-2 cells for 24, 48 or 72 h.  
As shown in Figure 36, the proliferation of cells incubated in the presence of 10 µM of 
Coumarin does not seem to be affected during the first 24 h (Figure 36 A) and is inhibited 
during 48 and 72 h (Figure 36 B) in comparison with the proliferation determined for control 
cells. However, while AAI inhibits the proliferation of cells, the presence of Coumarin does 
not have any effect on the proliferation of cells incubated with either 10 or 50 µM of AAI 
(Figure 36 A and 36 B). 
These results suggest that, in the experimental conditions, Coumarin does not induce a 
protection against toxicity of AAI for HK-2 cells. 
  
 
 
Figure 37: Effects of 3-TYP on the abundance of Ac-SOD2. Cells were seeded at 1.25x10
6
 cells/T25 dishes 
and incubated in the presence (CTL + 3-TYP) or in the absence (CTL) of 3-TYP and in the presence of 1 μM of 
AAI (1 µM) with (1 µM + 3-TYP) or without (1 µM) additional 10 µM of 3-TYP  for 24, 48 or 72 h (n=1). For 
this western blot analysis, 14 μg of proteins were loaded in the gel. Results are expressed as protein relative 
abundance and normalised by ɑ-tubulin used as a loading control. 
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The second molecule tested on HK-2 cells was the 3-TYP, an inhibitor of SIRT3 activity.  
c) Effects of 3-TYP on the acetylation status of SOD2, a sirtuin 3 target 
For western blot analysis, the loading control is not conclusive for Ac-SOD2 and leads to 
a difficult interpretation for 72 h (Figure 37).  
For 24 and 48 h, a slight decrease of the SOD2 acetylation was observed, when 
comparing control cells and control cells with 10 µM of 3-TYP or cells incubated with AAI 
and cells in the presence of AAI and 3-TYP. At 48 h, when comparing control cells and cells 
incubated in the presence of AAI, an increase of the SOD2 acetylation was also observed in 
the presence of AAI alone (Figure 37). 
However, surprisingly, it appears clear that the inhibition of SIRT3 using 10 µM of        
3-TYP does not increase the acetylation of SOD2 (Figure 37). 
  
Figure 38: Effect of 3-TYP on HK-2 cytotoxicity in the presence or in the absence of low concentration of 
AAI as assessed by LDH assay. Cells were seeded at 100000 cells/well in 24-well culture dishes and incubated 
in the presence or in the absence (CTL) of 1 μM of AAI for 24, 48 or 72 h. As indicated, in some conditions,      
10 µM of 3-TYP were added to cells for the same period of time. Results are expressed as means of percentages 
of cytotoxicity for three wells (n=1). 
 
 
 
Figure 39: Effect of 3-TYP on HK-2 cell proliferation in the presence or in the absence of low concentration 
of AAI as assessed by MTT assay. Cells were seeded at 100000 cells/well in 24-well culture dishes and 
incubated in the presence or in the absence (CTL) of 1 μM of AAI for 24, 48 or 72 h. As indicated, in some 
conditions, 10 µM of 3-TYP were added to cells for the same period of time. Results are expressed as 
absorbance unit and represent means of absorbance for three wells (n=1). 
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d) Effects of 3-TYP, an inhibitor of SIRT3, on cell toxicity and proliferation 
We wanted to test the putative effect of a SIRT3 inhibition on the sensitisation of HK-2 
cells to AAI. There is no cytotoxicity observed for cells incubated in the presence of 3-TYP 
alone or with 3-TYP in the presence of AAI (Figure 38).  
However, as shown in Figure 39, the proliferation of HK-2 cells incubated with or 
without AAI was inhibited by the presence of this inhibitor for the different timings. The 
impact was the same for control cells incubated in the presence of 10 µM of 3-TYP than for 
AAI-treated cells (1 µM) incubated in the presence of 3-TYP (Figure 39).  
These results suggest that 3-TYP does not induce sensitisation of HK-2 cells to AAI, but 
3-TYP slows down the cell proliferation. 
  
 
 
Figure 40: Effects of SRT2104 on the abundance of H3K9 (A for 24 h and B for 48 and 72 h). Cells were 
seeded at 1.25x10
6
 cells/T25 dishes and incubated in the presence (CTL + SRT2104) or in the absence (CTL) of 
SRT2104 and in the presence of 50 μM of AAI (50 µM) with (50 µM + SRT2104) or without (50 µM) additional 
25 µM of SRT2104  for 24 h (A). For 48 or 72 h (B), cells were incubated in the presence (CTL + SRT2104) or 
in the absence (CTL) of SRT2104 and in the presence of 10 µM of AAI (10 µM) with (10 µM + SRT2104) or 
without (10 µM) additional 25 µM of SRT2104 (n=1). For this western blot analysis, 14 μg of proteins were 
loaded in the gel. Results are expressed as protein relative abundance and normalised by ɑ-tubulin used as a 
loading control.  
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The third experienced molecule is the SRT2104, an activator of SIRT1 activity.  
e) Effects of SRT2104 on the acetylation status of H3, a sirtuin 1 target 
As observed in Figure 40 A, SRT2104 induces a decrease in the H3 acetylation at the    
24 h time-point, when comparing control cells and control cells with 25 µM of SRT2104. 
However, no modifications are observed, when comparing 50 µM of AAI and 50 µM of AAI 
with 25 µM of SRT2104 (Figure 40 A).  
For 48 and 72 h, the expression is slightly modified by the use of SRT2104, when 
comparing 10 µM of AAI and 10 µM of AAI with 25 µM of SRT2104 (Figure 40 B). 
 
 
  
 
Figure 41: Effect of SRT2104 on HK-2 cytotoxicity in the presence or in the absence of high concentration of 
AAI as assessed by LDH (A for 24 h; B for 48 or 72 h) assay. Cells were seeded at 100000 cells/well in 24-well 
culture dishes and incubated in the presence or in the absence (CTL) of 50 μM of AAI for 24 h (A) or in the 
presence or in the absence (CTL) of 10 µM of AAI for 48 or 72 h (B). As indicated, in some conditions, 25 µM of 
SRT2104 were added to cells for the same period of time. Results are expressed as means of percentages of 
cytotoxicity for three wells (n=1).  
 
 
 
Figure 42: Effect of SRT2104 on HK-2 cell proliferation in the presence or in the absence of high 
concentration of AAI as assessed by MTT (A for 24 h; B for 48 or 72 h) assay. Cells were seeded at 100000 
cells/well in 24-well culture dishes and incubated in the presence or in the absence (CTL) of 50 μM of AAI for  
24 h (A) or in the presence or in the absence (CTL) of 10 µM of AAI for 48 or 72 h (B). As indicated, in some 
conditions, 25 µM of SRT2104 were added to cells for the same period of time. Results are expressed as 
absorbance unit and represent means of absorbance for three wells (n=1). 
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f) Effects of SRT2104, an activator of SIRT1, on cell toxicity and proliferation 
Regarding the cytotoxicity, the molecule SRT2104 does not seem to be toxic at the tested 
concentration (25 µM) and does not change the increase in LDH released by cells incubated 
for 24 h with 50 µM of AAI (Figure 41 A). However, there is a slight increase (from 10 to   
17 %) in the toxicity observed in cells incubated in the presence of 25 µM of SRT2104 for   
72 h (Figure 41 B). A slight decrease (from 34 to 23 %) in the toxicity is only observed for  
48 h, when comparing the release by cells incubated with 10 µM of AAI and cells incubated 
with 10 µM of AAI in the presence of 25 µM of SRT2104 (Figure 41 B).  
As shown in Figure 42 A, the proliferation of HK-2 cells was not affected by the presence 
of this activator at a concentration of 25 µM during 24 h, but there is a decrease in cell 
proliferation at 48 and 72 h of incubation (Figure 42 B). In addition, the presence of SRT2104 
in the culture media does not change the inhibitory effect of AAI on the proliferation of HK-2 
cells incubated with 50 µM of AAI (for 24 h) or 10 µM of AAI (48 or 72 h) (Figure 42 A and 
42 B, respectively). 
As an effect has only been only seen for a 48 h-incubation time, it is very difficult and 
even impossible to draw a conclusion on the putative effect of the SIRT1 activator on the 
toxicity for HK-2 cells.  
 
  
 
 
 
Figure 43: Effects of EX527 on the abundance of H3K9. Cells were seeded at 1.25x10
6
 cells/T25 dishes and 
incubated in the presence (CTL + EX527) or in the absence (CTL) of EX527 and in the presence of 1 μM of AAI 
(1 µM) with (1 µM + EX527) or without (1 µM) additional 10 µM of EX527 for 24, 48 or 72 h (n=1). For this 
western blot analysis, 14 μg of proteins were loaded in the gel. Results are expressed as protein relative 
abundance and normalised by ɑ-tubulin used as a loading control. 
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The fourth and last tested molecule is the EX527, an inhibitor of SIRT1 catalytic activity.  
g) Effects of EX527 on the acetylation status of H3, a sirtuin 1 target 
Despite the quality of the western blot, one can observe that the presence of 10 µM of 
EX527 does not change the acetylation level of the histone protein when compared to the 
abundance of the acetylated form of the H3 in control cells for 24, 48 or 72 h. In addition, a 
slight increase in the H3 acetylation is found in cells incubated with 1 µM of AAI for 24, 48 
or 72 h (Figure 43). Surprisingly, the acetylation seems to be reduced in cells incubated with  
1 µM of AAI in the presence of the SIRT1 inhibitor for each time tested in this work.   
  
 
 
Figure 44: Effect of EX527 on HK-2 cytotoxicity in the presence or in the absence of low concentration of 
AAI as assessed by LDH assay. Cells were seeded at 100000 cells/well in 24-well culture dishes and incubated 
in the presence or in the absence (CTL) of 1 μM of AAI for 24, 48 or 72 h. As indicated, in some conditions,      
10 µM of EX527 were added to cells for the same period of time. Results are expressed as means of percentages 
of cytotoxicity for three wells (n=1). 
 
 
Figure 45: Effect of EX527 on HK-2 cell proliferation in the presence or in the absence of low concentration 
of AAI as assessed by MTT assay. Cells were seeded at 100000 cells/well in 24-well culture dishes and 
incubated in the presence or in the absence (CTL) of 1 μM of AAI for 24, 48 or 72 h. As indicated, in some 
conditions, 10 µM of EX527 were added to cells for the same period of time. Results are expressed as 
absorbance unit and represent means of absorbance for three wells (n=1). 
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h) Effects of EX527, an inhibitor of SIRT1, on cell toxicity and proliferation 
The molecule used at 10 µM does not induce any toxicity of the cells and the presence of 
EX527 at the concentration used for this experiment does not affect the LDH release 
measured for cells incubated with 1 µM of AAI for 24, 48 or 72 h (Figure 44). 
As shown in Figure 45, the proliferation of HK-2 cells is inhibited in the presence of 
either 1 µM of AAI or the inhibitor of SIRT1 at 10 µM, but the effect is mainly visible 
between 48 and 72 h. In addition, the presence of EX527 does not have any effect on the 
proliferation of cells incubated with 1 µM AAI (Figure 45). 
These results suggest that EX527 does not induce a sensitisation of HK-2 cells to AAI 
toxicity. 
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Discussion 
 
Aristolochic acid nephropathy (AAN) is a worldwide problem, which was initially 
reported as a consequence of the ingestion of slimming pills containing aristolochic acids 
(AA), genotoxic, cytotoxic and carcinogenic compounds (Romanov et al., 2015; Shibutani et 
al., 2007). This nephropathy leads to an extensive and progressive interstitial fibrosis, mainly 
located in the cortex and characterized by a tubular atrophy of proximal tubules and by 
inflammatory cells infiltration in the interstitial tissue (Debelle et al., 2008; Jadot et al., 
2017b; Vanherweghem et al., 1993). Tubular atrophy is the consequence of the loss of 
integrity of the proximal tubular epithelial cells (PTEC). Indeed, it was described that PTEC 
constitute the preferential cell target of AA (Debelle et al., 2008; Depierreux et al., 1994; 
Nortier et al., 2015). 
Therefore, for the experiments described in this work, we used human kidney-2 (HK-2) 
cells, which are PTEC from normal adult human kidney, immortalized by human 
papillomavirus-16 (HPV-16). Indeed, it is an immortalized human cell line realized from 
PTEC, which are the main target of AA. Moreover, HK-2 possess many characteristics which 
are found into physiological PTEC (Ryan et al., 1994). 
Sirtuins (SIRT) 1 and 3 are NAD
+
-dependent enzymes catalysing the deacetylation of 
many different substrates, which were already investigated in other kidney diseases models 
such as cisplatin- (Morigi et al., 2015), ischemia-reperfusion (I/R)- (Hasegawa et al., 2010) or 
sepsis-induced acute kidney injury (AKI) models (Zhao et al., 2016). In these models, SIRT1 
was reported as protective against oxidative stress triggered by I/R in C57Bl/6 mice 
(Hasegawa et al., 2010). SIRT3 was also reported as protective against renal mitochondrial 
damages in cisplatin- and sepsis-induced AKI models (Morigi et al., 2015; Zhao et al., 2016). 
As regards in vitro studies, focus of the present work, it was reported that 
overexpression of SIRT3 in normal rat kidney tubular epithelial (NRK52E) cells allows the 
suppression of angiotensin II (Ang II)-induced decrease in mitochondrial membrane potential. 
Ang II plays an important role in the progression of renal injury and most particularly in 
progressive renal fibrosis. He and his colleagues (2018) have also demonstrated that SIRT3 
overexpression reversed the superoxide dismutase 2 (SOD2) accumulation induced by Ang II. 
This study suggests that SIRT3 might ameliorate mitochondrial dysfunction (He et al., 2018). 
I/R can cause AKI and is characterized by, among others, increased production of ROS 
and mitochondrial damages. I/R injury (IRI), causing hypoxia/reoxygenation, increases cell 
death, reduces mitochondrial membrane potential and reduces SIRT3 expression in HK-2 
cells. The expression of SIRT3 can be preserved and the mitochondrial alterations can be 
attenuated by the use of the dexmedetomidine molecule, an α2-adrenoreceptors agonist. This 
molecule inhibits mitochondrial disruption, likely by preventing mitochondrial membrane 
potential impairment and cytochrome c release. Therefore, in vitro, dexmedetomidine 
possesses protective effects and up-regulates SIRT3. In turn, SIRT3 contributes to 
dexmedetomidine effects by preserving mitochondrial structure and function (Si et al., 2018). 
The first part of the present study was to determine the optimal concentration and 
incubation time in the presence of AAI that are minimizing the toxicity without cell death in 
order to study AAI effects on the expression of SIRT1 and SIRT3. It was observed that 
concentrations used in this work are not toxic, as compared to 10 μM which was used as a 
positive control because known as cytotoxic (Yang et al., 2010). Indeed, these authors showed 
that HK-2 cells incubated with a concentration of 14 µM of AAI arrest cell cycle at G2/M 
checkpoint after 48 h of incubation. In addition, Romanov and his colleagues have shown that 
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a concentration of AAI as low as 4 µM already induces activation of DNA damage signalling 
pathway and cell cycle arrest in G2/M phase (Romanov et al., 2015). 
The significant decrease in the viability observed for 0.25 μM at 72 h time-point is 
difficult to interpret as the toxicity is not observed for higher concentrations and is most likely 
due to an experimental problem. In addition, at 10 μM, a decrease in cell proliferation was 
observed, when compared to control cells, as revealed by both MTT and LDH assays. The 
second tests confirm the first ones. In addition, it was demonstrated that only the toxic 
concentration of 10 µM does affect the proliferation of HK-2 cells for a 72 h-incubation. 
In the second part of this work, ATP contents were determined in HK-2 cells exposed to 
AAI. Indeed, it was demonstrated that, in Sprague-Dawley rats intoxicated during 7 days with 
5, 20 or 80 mg/kg/day, ATP contents decrease in a concentration-dependent manner (Jiang et 
al., 2013). A decrease in ATP contents was only observed for an AA concentration of 50 µM. 
Thus, subtoxic concentrations should not affect the morphology of the mitochondrial 
population in HK-2 cells. Therefore, the morphology of the mitochondrial population in HK-2 
cells exposed to low concentrations of AAI should be analysed to confirm previous results 
and to establish a correlation between mitochondrial fragmentation and decrease in ATP 
contents. In the thesis of P. Mosseray, the mitochondrial network has been assessed after   
HK-2 incubation in the presence of 5 µM of AAI during 24, 48 or 72 h. The morphology of 
the mitochondrial population was not affected in these conditions (data not shown – 
unpublished data, P. Mosseray, ongoing PhD thesis). 
As described in the introduction, AAI can possibly be secreted outside PTEC by 
multidrug resistance-associated proteins (MRP) 2 and 4 transporters and these transporters 
need ATP to carry organic anions (Hagos and Wolff, 2010). However, it appears that AAI 
decreases cellular ATP contents. This impairment could potentially induce a reduction of AAI 
transport in PTEC, leading to an accumulation of AAI and, finally, result in an increase in the 
toxicity induced by AA exposure (Hagos and Wolff, 2010). 
A transient increase in ATP contents in cells, incubated in the presence of AAI in a 
range between 1 and 50 µM, was only observed for a 24 h-incubation. It might be supported 
by several explanations: 1) a potential activation of glycolysis to compensate a mitochondrial 
injury, 2) a reduction of ATP-consuming biological processes or an increase of the ATP 
production, in order to spare and preserve ATP contents, and 3) an attempt to adjust and 
compensate in response to stress. For example, related to the second point, on the one hand, it 
could be a reduction of ATP-consuming processes such as protein synthesis, RNA/DNA 
synthesis, Na
+
 cycling, Ca
2+
 cycling and proton leak (Wieser and Krumschnabel, 2001). On 
the other hand, it could be a stimulation of the ATP production induced by the activation of 
Ca
2+
-signalling cascade to compensate the energy loss induced by calcium signals. These 
hypotheses could be tested by the use of thapsigargin or ionomycin, two molecules able to 
increase the calcium concentration, in order to assess the effects of an increase of calcium-
concentration on ATP contents (Voronina et al., 2010). Nevertheless, these preliminary results 
need to be confirmed. 
Another perspective will be to assess the dynamin-related protein 1 (Drp1) 
phosphorylation level in HK-2 cells incubated in the presence of AAI (from 10 µM up to     
50 µM). Indeed, it was demonstrated that, in cultured tubular cells, ATP depletion caused 
Drp1 translocation to mitochondria and mitochondrial fragmentation, leading to cytochrome c 
release and apoptosis (Tabara et al., 2014). In fact, during ATP depletion, Drp1 
dephosphorylation at Ser637 was observed and contributes to mitochondrial fragmentation 
(Zhan et al., 2013). 
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Zheng and colleagues also reported defects in mitochondrial structure and a decrease in 
ATP levels in a model of iron overload in mesenchymal stromal cells (Zheng et al., 2018). It 
is also known that high concentrations of AAI (20 or 100 μM) induce an increase of ROS 
concentrations in NRK-52E (Wu et al., 2015). In fact, in a context of oxidative stress, 
mitochondrial fragmentation is correlated to reduced ATP levels in a model of iron overload 
(Zheng et al., 2018). Indeed, high ROS levels can lead to defects in mitochondrial structure by 
damaging the mitochondrial respiration chain and inhibiting the synthesis of DNA and 
proteins. In addition, mitochondrial dynamics by fusion and fission process are closely linked 
to cellular energy metabolism and the mitochondrial morphology can also be regulated by 
ATP concentration (Zheng et al., 2018). The results of the present study developed and based 
on another model will not confirm or invalidate the results developed by Zheng and his team. 
Therefore, the morphology of the mitochondrial population in HK-2 cells exposed to AAI 
should be analysed in a context of oxidative stress. 
Several perspectives for future studies about mitochondria exist. For example, it is 
possible to measure mitochondrial respiration levels, which are a useful indicator of 
mitochondrial biogenesis. It could be performed by the assessment of the carbonyl cyanide-4 
(tri-fluoromethoxy) phenylhydrazone (FCCP)-uncoupled respiration, a marker of maximal 
mitochondrial ETC activity of renal proximal tubular cells. It was reported that this 
respiration increased when the mitochondrial biogenesis increases (Whitaker et al., 2016). A 
second option would be the evaluation of the glutathione/oxidized glutathione (GSH/GSSG) 
ratio, as the oxidative stress and the mitochondrial damages seem be linked (Zheng et al., 
2018) and as AAI-intoxication induces GSH depletion in rats (Yu et al., 2011). If this ratio 
increases, the oxidative stress decreases (Ouyang et al., 2019). We could determine this by a 
colorimetric assay based on the reaction between 5’, 5’-dithiobis-2-nitrobenzoic acid (DTNB) 
and GSH to form 2-nitro-5-thiobenzoic acid (TNB), which exhibits maximum absorbance at 
412 nm. The intensity of the absorbance is proportional to the GSH level in the sample 
(ScienceCell
TM
, Research Laboratories). In addition, after I/R in HK-2 cells, it was observed a 
decrease of the expression levels of three mitochondrial respiratory chain genes: 1) adenosine 
triphosphate synthase subunit β (ATPS-β), 2) nicotinamide adenine dinucleotide: ubiquinone 
oxidoreductase subunit B8 (NDUFB8) and 3) cytochrome c oxidase subunit 1 (COX1). As 
these proteins are associated with mitochondrial damages, another possibility of additional 
study could be to assess protein levels of ATPS-β, NDUFB8 and/or COX1 by western blot 
analysis (Huang et al., 2018). 
In the third part of the study, we aimed to investigate the expression levels of SIRT1 
and SIRT3 in HK-2 cells exposed to subtoxic concentrations of AAI, at both protein and 
mRNA levels. No changes were observed in cells exposed to subtoxic concentrations, mainly 
for SIRT1. The expression of SIRT3 was more variable at protein level. The mechanisms 
responsible for a lower abundance of the enzymes with these different concentrations should 
be analysed in a future development. 
It was reported that SIRT1 expression increases with the cellular accumulation of ROS 
(Hasegawa et al., 2008). In the current work, SIRT1 levels are unchanged; it is probable that 
the subtoxic concentrations induce no or minor oxidative stress. As regards SIRT3, this 
protein was studied in a model of cisplatin-induced AKI in C57BL/6J mice and is known to 
have antioxidant properties. This nephropathy model is characterized by tubular cells 
impairment and one of the major tubular cell injuries in this model is the mitochondrial 
dysfunction, which is manifested by oxidative stress, inflammation and cell damages. A 
decrease of SIRT3 expression was reported as exacerbating cisplatin-nephrotoxicity by an 
impairment of the mitochondrial morphology (Huang et al., 2019). The SIRT3 expression has 
no significant modification in the present study, but it would be interesting in the future to 
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evaluate oxidative stress level, by the assessment of SOD2 acetylation level for example, to 
know whether SIRT3 protects against this stress. Indeed, it was demonstrated that ROS levels 
are tightly linked with SIRT3 activity (Huang et al., 2019). The hypothesis, to confirm during 
upcoming studies, would be that the tested subtoxic concentrations should not trigger 
oxidative stress, inflammation or mitochondrial damages. 
The last part of this work covered an assessment of the effect on the one hand on the 
acetylation of specific targets and on the other hand on the cytotoxicity and the cell 
proliferation, either by activation of SIRT1 and SIRT3 or by inhibition of these proteins, 
respectively by two molecules for inhibition and two molecules for activation. 
First, we will discuss about the effects of an activator (Coumarin) and an inhibitor      
(3-TYP) of SIRT3 activity. 
The selected activator of SIRT3 activity was the Coumarin. It is extended into the 
NAD
+
 binding pocket of SIRT3 and it has been shown that Coumarin treatment in primary 
cultured cortical astrocytes isolated from rats induces several effects. This treatment, 
increasing SIRT3 activity, activates SOD2 and, by the way, reduces the mitochondrial 
superoxide level and the Lys68 acetylation of SOD2 (Lu et al., 2017). In this work, a slight 
decrease of the SOD2 acetylation was observed at 24 h, only in control cells incubated with 
10 µM of Coumarin. An increase in the SOD2 acetylation was observed for 48 or 72 h in cells 
incubated in the presence of AAI alone, but this acetylation is decreased in cells exposed to  
10 µM of AAI and 10 µM of Coumarin for 48 h-incubation. We can postulate that AAI would 
inactivate SOD2 and we can hypothesize an activation of SIRT3 by Coumarin, which can be 
confirmed by the measure of SIRT3 protein or mRNA expression and the SIRT3 activity 
level. Nevertheless, the activation of SIRT3 seems not sufficient to induce a protection against 
an exposure of 10 or 50 µM of AAI. Indeed, in this study, we observed a similar cytotoxicity 
in cells incubated with AAI alone compared to cells with AAI and Coumarin. For future 
experiments, the concentration of Coumarin could be increased in order to obtain a stronger 
effect of the activation of SIRT3. 
The second molecule, 3-TYP, can inhibit SIRT3 activity to a similar extent compared to 
nicotinamide. It was reported that, after an exposure of HeLa cells during 1-6 h in the 
presence of 1 mM of this compound, the acetylation of mitochondrial proteins increases (Galli 
et al., 2012). After, it was shown in a model of cadmium-induced hepatotoxicity in human 
hepatocellular carcinoma cell line (HepG2) that an overexpression of SIRT3 mRNA allows:  
1) a reduction of the acetylated-SOD2, 2) an increase of SOD2 activity and, finally, 3) a 
decrease in mitochondrial ROS production. The activity of SOD2 is inversely proportional to 
its acetylation. In this study, the use of 50 µM of 3-TYP attenuated these modifications (Pi et 
al., 2015). In fact, SOD2 activity is mediated by SIRT3. SIRT3 reduces cellular levels of ROS 
according to the levels of SOD2, by the deacetylation of two critical lysine residues on SOD2, 
promoting then its antioxidative activity. More importantly, the ability of SOD2 to reduce 
cellular levels of ROS and to promote resistance to oxidative stress is enhanced considerably 
by SIRT3. Moreover, 3-TYP inhibits only the activity and not the expression of SIRT3 (Zeng 
et al., 2016). However, in this work, only a slight decrease of the SOD2 acetylation was 
observed for 24 or 48 h, in cells exposed to 10 µM of 3-TYP. Moreover, an increase of 
acetylated-SOD2 was observed in the presence of AAI alone for 48 h. Nevertheless and 
surprisingly, the inhibition of SIRT3 with this concentration of inhibitor does not increase the 
acetylation of SOD2. To know whether the concentration of   3-TYP used in this work is able 
to induce a modification of SIRT3, we could evaluate the enzymatic SIRT3 activity by a 
fluorimetric assay. And as regards the cell proliferation and the cytotoxicity, it appears that  
10 µM of 3-TYP is not toxic for HK-2 cells for 24, 48 or 72 h-incubation periods, but that 
affects only the proliferation. No sensitisation was observed in this work. 
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Secondly, we will discuss about the effects of an activator (SRT2104) and an inhibitor 
(EX527) of SIRT1 activity. 
The selected activator of SIRT1 activity was the SRT2104, our third molecule. 
Previously, it was reported that transgenic mice overexpression SIRT1 shows neuroprotection 
during Huntington disease (HD), whereas a deficiency of SIRT1 exacerbates the HD 
phenotype. Jiang and his team have used SRT2104 in N171-82Q HD mice in order to activate 
SIRT1 activity. They have provided the evidence that this compound ameliorates motor 
deficits, rescues brain atrophy, and extends survival in HD mouse model (Jiang et al., 2014). 
In addition, the use of 100 mg/kg of SRT2104 in C57BL/6 mice allows an overall 
downregulation of inflammatory pathways in muscles. Moreover, the exposure of 3 µM of 
SRT2104 on C2C12 myofibroblasts induces a lower acetylation of the p65 subunit of nuclear 
factor-kappa B (NF-кB), which suggests that SRT2104 suppresses NF-кB activity. And as 
regards oxidative stress, it is reported in the study of Mercken (2014) that, in an experimental 
model of atrophy using mice, short-term SRT2104 treatment preserves bone and muscle mass 
and that levels of SOD2 were increased only in muscles and not in liver (Mercken et al., 
2014). It was also established that 100 mg/kg of SRT2104 reduces the expression of oxidative 
stress and inflammation markers in the aortic endothelium of C57BL/6 mice, in addition to 
the increase of SIRT1 protein expression (Wu et al., 2018). In this work, the histone H3 
acetylation decreases at the 24 h for cells incubated in the presence of 25 µM of SRT2104. 
And at 48 or 72 h, the expression is slightly modified for cells exposed to both 10 µM of AAI 
and 25 µM of SRT2104. At 72 h-incubation, the acetylation of cells incubated with both AAI 
and SRT2104 increases irrationally. It might be due to the instability of the molecule and we 
have to keep in mind that these results come from only one experiment. In addition, the use of 
25 µM of SRT2104 induces a decrease of the HK-2 cells proliferation between 48 and 72 h, 
accompanied by an increase of the cytotoxicity. But a slight protection, marked by a decrease 
of the toxicity, is observed at 48 h time-point, when comparing cells exposed to both 10 µM 
of AAI and 25 µM of SRT2104 and cells exclusively exposed to 10 µM of AAI. From these 
results, it is very difficult to draw a conclusion on the putative effect of SRT2104 on the 
cytotoxicity for HK-2 cells. In this case, the concentration of the activator could be increased 
in order to obtain a stronger effect or the stability of SRT2104 could be studied. 
The last molecule, EX527, is a selective inhibitor of SIRT1’s catalytic site (Solomon et 
al., 2006). It seems that, after formation of a complex SIRT1 - substrate, EX527 binds to this 
complex and blocks the product release (Blum et al., 2011). In a model of I/R injury in 
C57BL/6J mice evaluating the protective effect of melatonin treatment and its potential 
effects on the cerebral mitochondrial redox state and function, it was demonstrated that 
EX527 reversed the beneficial effects of melatonin by SIRT1 activity decrease (Yang et al., 
2015). In addition, in the study of Solomon (2006), it was reported that the use of 1 µM of 
EX527 does not influence the cell proliferation (Solomon et al., 2006). In the present study, 
EX527 does not affect the acetylation of histone H3 for 24, 48 or 72 h-incubation periods, but 
the use of 1 µM of AAI increases the acetylation level. Surprisingly, in the presence of both 
AAI and EX527, a decrease of the H3 acetylation is observed. It might be due to an 
interaction between both molecules, which would inhibit the effect of EX527 alone. In 
addition, a decrease of the cell proliferation of control cells incubated in the presence of 10 
µM of EX527 was only observed after 72 h, with or without 1 µM of AAI. That might 
suggest that cell proliferation is affected by the inhibition of the catalytic activity of SIRT1 
and that 10 µM of EX527 does not induce a sensitisation of HK-2 cells to AAI cytotoxicity. 
In perspectives to this study, we might evaluate the SIRT1 expression to know whether the 
concentration of EX527 used is sufficient to modify the expression of the enzyme. 
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Moreover, additional in vitro experiments could be conducted by using other models, 
either microfluidic organs-on-chips (Chang et al., 2017) or integrated discrete multiple organ        
co-culture (IdMOC) (Gayathri et al., 2015). These co-culture methods allow to identify the 
toxicological mechanisms of hepatic and renal enzymes in the activation or detoxification of 
AAI in humans and the organ-organ interactions (Chang et al., 2017).  
Both models have several advantages. The first is to get complete information about the 
induction or inhibition of hepatic Phase I and Phase II enzymes. As a result, the cellular 
changes that happened to the target organ - the kidney in this case - can be obtained 
simultaneously. Another is that the major pathway involved in the drug metabolism can be 
identified by the use of selective inhibitors or inducers of the selected specific pathway. A 
third is the identification of the drug-drug interaction, in which a drug can affect the metabolic 
stability of the other drug (Gayathri et al., 2015). In addition, these models also allow to 
mimic in vivo situation under in vitro condition (Gayathri et al., 2015). 
The first approach, microfluidic organs-on-chips, is also called micro-physiological 
systems (MPS) and allows to link a human kidney MPS to a human liver MPS via 
polyethylene tubing. The kidney MPS recapitulates the renal proximal tubule by the use of 
primary PTEC (Chang et al., 2017). Primary human PTEC were seeded inside the MPS filled  
with type I collagen, allowing to adhere for 24 hours, and perfusion of media was initiated 
inside the lumen. Cells inside the lumen exhibited characteristic features of mature PTEC 
(Bajaj et al., 2018; Chang et al., 2017). This MPS 1) exhibits long-term viability (up to four 
weeks), 2) preserves polarized expression and function of proteins crucial for absorptive and 
secretory transport, 3) reacts to physiological stimuli and 4) performs biochemical synthetic 
activities (Weber et al., 2016). The second MPS is composed of human hepatic parenchymal 
cells (Chang et al., 2017). These cells possess high viabilities and are operational for long-
term culture (Chang et al., 2017). In addition, they are the closest model for the liver in vivo 
(Gayathri et al., 2015) and have human hepatic metabolism capacity (Li, 2007b). Indeed, they 
maintained various intact cell properties such as the intact cell membrane with active 
transporter functions, complete and uninterrupted metabolic pathways, and metabolic 
enzymes and cofactors at physiologically relevant concentrations (Li, 2015). 
The second device allows the use of primary cells or organ slices, multiple organ 
interaction and analysis of metabolic cytotoxicity. The concept is the following: a culture 
plate possesses chambers containing wells, which have six small inner wells. This provide a 
culture with six different cell types, three cell types in duplicate or two cell types in triplicate. 
The diverse cell types, after culturing in their own media, are interconnected by filling the 
chamber with a universal medium (Gayathri et al., 2015), which is akin to the blood 
circulation connecting organs in the human body (Li, 2007a). In this case, cell types could be 
the same that for the MPS: primary PTEC and hepatocytes. 
By the use of several cell types simultaneously, IdMOC and MPS are less                
time-consuming methods (Gayathri et al., 2015). Moreover, these approaches have the ability 
to evaluate each cell type separately for cytotoxicity after co-culturing and under              
near-identical experimental conditions (Li, 2007b; Li, 2015) and well-to-well or plate-to-plate 
differences are eliminated for the IdMOC (Li, 2009). 
After the establishment of one of these models of co-culture, it might be possible to 
investigate the effects induced by AAI on liver and renal cells with regard to inflammation, 
oxidative stress or mitochondrial damages in order to mimic most the complete 
metabolization of AAI. 
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Finally, additional in vivo experiments could be performed. The AAN mice model, 
previously developed in our laboratory (Jadot et al., 2017a), should be tested in SIRT3
-/-
 mice 
or in transgenic mice overexpressing SIRT3. 
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Annex I - Micrographs of cell proliferation of HK-2 cells overtime 
 
Figure 46: Micrographs of cell proliferation of HK-2 cells overtime. Cells were seeded at different densities in 24-well culture plate during 6, 24, 48 or 72 h.  
Magnification 60x. 
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Figure 46: Micrographs of cell proliferation of HK-2 cells overtime. Cells were seeded at different densities in 24-well culture plate during 6, 24, 48 or 72 h.  
Magnification 60x.
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Annex II - Effects of low concentrations of AAI on cell proliferation 
 
 
Figure 47: Effect of low concentrations of AAI on HK-2 cell assessed by MTT assay. Cells were seeded at 
100000 cells/well in 24-well culture dishes and incubated in the presence of 0, 0.1, 0.25, 0.5, 0.75 or 1 μM of 
AAI for 12, 24, 48 or 72 h. Results are expressed as absorbance unit and represent means of absorbance for 
three wells (n=1).
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Annex III - Micrographs of cell proliferation of HK-2 cells 
 
Figure 48: Micrographs of cell proliferation of HK-2 cells seeded at 100 000 cells/well in 24-well culture plate or 1.25x10
6
 cells/T25 culture flask and incubated with 0.1, 
0.25, 0.5, 0.75, 1, 10 or 50 µM of AAI during 12, 24, 48 or 72 h with AAI. Magnification 100x. 
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